Childhood epilepsy: alternative methods for assessing treatment strategies and outcome by Carpay, J.A. (Hans)
CHILDHOOD EPILEPSY: 
ALTERNATIVE METHODS 
FOR ASSESSING 
TREATMENT STRATEGIES 
AND OUTCOME 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
CHILDHOOD EPILEPSY: 
ALTERNATIVE METHODS FOR ASSESSING 
TREATMENT STRATEGIES AND OUTCOME 
(KINDEREPILEPSIE: ALTERNATIEVE METHODEN 
OM BEHANDELINGSSTRATEGIE EN UITKOMST IN KAART TE BRENGEN) 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE 
ERASMUS UNIVERSITEIT ROTIERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR P.W.c. AKKERMANS M.A. 
EN VOLGENS BESLUIT VAN HET COLLEGE VOOR PROMOTIES 
DE OPEN BARE VERDEDIGING ZAL PLAATSVINDEN OP 
VRIJDAG 21 NOVEMBER 1997 OM 11.00 UUR 
DOOR 
JOHANNES ANTON CAR PAY 
GEBOREN TE AMSTERDAM 
PROMOTIECOMMISSIE 
Promotor: 
Overige leden: 
Prof. dr W.F.M. Arts 
Prof. dr F.G.A. van der Meche 
Prof. dr A.C.B. Peters 
Prof. dr J. Passchier 
Prof. dr H.A. Buller 
This study has been supported by the Dutch National Epilepsy Fund and the 
dr Eduard Hoelen Stichting. 
This thesis was sponsored by: Merck Sharp & Dohme B.Y., GlaxoWellcome B.V., 
Novo Nordisk Farma B.V., Novartis Phanna B.V.,Janssen-Cilag B.V., Sanofi 
Winthrop B.V., Eli Lilly Nederland B.V., Yamanouchi Pharma B.V., Zeneca 
Famla B.V., Ipsen Fannaceulica B.V., Asta Medica B.V., Schering Nederland B.V. 
en UCB Pharma B.V. 
Cover: "Activities Jor wllich restrictions arc oJteli advised arc batllillg, swilllming. 
climbing alld riding II bicycle." (Chapter 7). 
CONTENTS 
1. Introduction ............................................. 7 
2. Epilepsy in childhood: An audit of clinical practice ................ 9 
3. Review. Outcome assessment in epilepsy: Available 
rating scales for adults and methodological issues 
pertaining to the development of scales for 
childhood epilepsy ........................................ 25 
4. Parent-completed scales for measuring seizure severity 
and severity of side-effects of antiepileptic drugs in 
childhood epilepsy: Development and psychometric 
analysis. . .............................................. 39 
5. Seizure severity in children with epilepsy: 
A parent-completed scale compared with clinical data ............ .55 
6. Subjective side-effects of antiepileptic drugs: Assessment 
by using a parent-completed scale ............................ 73 
7. Disability due to restrictions in childhood epilepsy. . ............. 91 
8. Summary and conclusion . ............................... .. 107 
9. Samenvatting, cOllclusie en weergave van de 
toegepaste schalen ....................................... 111 
10. References ............................................. 126 
11. List of co-authors and affiliations ............................ 135 
12. List of abbreviations ...................................... 137 
13. Acknowledgements ...................................... 139 
14. Curriculum vitae . ...................................... . 141 
15. List of publications. . .................................... 143 

1 INTRODUCTION 
Epilepsy -defined as recurrent unprovoked seizurcs- is one of the most 
common neurological disorders in childhood and adolescence, with an incidence 
ranging from 50 to 100 per 100.000." The severity of epilepsy intuitively ranges 
from 'mild' to 'severe', depending on various factors such as seizure frequency 
and severity, duration of illness, antecedent and concomitant illness, and re-
sponse to treatment. 
Most children with epilepsy are treated with antiepileptic drugs (AEDs). 
The purpose of treatment is to improve the child's quality of life (QoL) by sup-
pressing the seizures. There is no evidence that all seizures require treatment be-
cause seizures cause brain damage, or because untreated epilepsy is a progressive 
disorder. Hence, the adverse consequences of treatment (e.g. Side-effects) may 
outweigh the benefit of treaunent (suppression of seizures), Most children with 
epilepsy respond very weB to treatment with AEDs. However, in about one third 
of children with newly developed epilepsy a complete remission from seizures is 
not reached within a short period of time. For these children, it is especially dif-
ficult to find the best possible balance between seizure control and side-effects of 
medication. It is probable that 'acceptable control' can be achieved despite recur-
rent seizures, and that complete eradication of seizures -at the cost of more side-
effects- is not always in the child's best interest. 
Chapter 2 of this thesis addresses some controversies in the treatment of 
children with new onset epilepsy. It explores how many children in an inception 
cohort of the Dutch Study of Epilepsy in Childhood were not treated with AEDs, 
and describes the strategies followed by the clinicians when treatment with AEDs 
was considered necessary. An attempt was made to identify children with 'ac-
ceptable control' despite recurrent seizures. The description of outcome in this 
study was limited to retention on an AED or remission from seizures. 
For a very long time, outcome assessment in epilepsy has been restricted to 
seizure frequency or duration of remission. The limitations of the traditional ap-
proach towards outcome assessment in epilepsy become apparent when we real-
ize that 'the best possible balance between seizures and side-effects' or 'acceptable 
control' are essentially subjective terms. Therefore, outcome assessment in 
epilepsy may be more complete when measures addressing such subjective issues 
are included. In the past decade, some additional, alternative methods to im-
prove outcome assessment in epilepsy have been proposed. We felt that the use 
of QoL instruments for outcome assessment was also appropriate for children 
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with epilepsy. 
Chapler 3 provides a review of the literature on outcome assessment in 
epilepsy, with an emphasis on clinical issues such as the severity of seizures and 
side-effects of medication and their relation to quality of life. Chapters 4,5,6 a"d 7 
report our efforts to develop measures of seizure severity, severity of side-effects 
and disability due to restrictions in children with epilepsy as perceived by their 
parents. We provide data on the reliability and validity of these scales and their 
association with various clinical variables. 
According to a recent Lancet Editorial, there is a trend in clinical research 
to make 'subjectivity scientific',81 Unfortunately, clinicians are often not familiar 
with the required psychometric techniques, which are provided by the social sci-
ences. A comprehensive description of basic psychometric theory, which may 
help the reader to enjoy some of the chaplers in this thesis, can be found else-
where, ~S.l(\3 
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AN AUDIT OF CLINICAL PRACTICE. 
Hans A. Carpa)', MD; Willcm F.M. Arts, MD, PhD; Ada T. Geerts, MSc; Hans 
Stroink, MD; Oebele T'. Brouwer, MD, PhD; A.C. Boudc\\1'Il Peters, MD, phD; 
and Cecs A. van Donse!a"r, MD, PhD. 
Archives oJ NClirology, accepted for publication. 
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2,0 ABSTRACT 
Bachgrolllld: It is not known how many children with epilepsy may not need 
treatment with antiepileptic drugs (AEDs), how many respond unsatisfactorily to 
subsequent treatment regimens and how many achieve 'acceptable control' des-
pite lack of remission. 
Methods: In a prospective multicenter hospital-based study, 494 children with a 
broad range of seizure types and epilepsies were followed for at least 2 years. 
There was no standard treatment protocol. vVe describe the treatment strategies 
applied to these children by the neurologists in charge and outcome with respect 
to remission from seizures. 
Resillts: Treatment was initially withheld in 29% and after two years 17 % of the 
children still had not received any AED. There were no serious complications 
from withholding treatment. Of the children treated with AEDs, 60% were still 
using the first AED after 2 years. 80% received mono- and 20% poly therapy. 
Especially children with severe symptomatic epilepsies like the West or Lennox 
syndrome received poly therapy early on in the course of treatment. V\'hen three 
regimens had failed, the chance of achieving a remission of more than onc year 
with subsequent regimens was 10%. 15 of 50 children receiving AEDs in whom 
the 'longest remission ever' was less than 6 months did, nevertheless, achieve 
acceptable seizure control according to the neurologist in charge of treahnent. 
Hence, of 494 children, only 35 (7%) developed an intractable form of epilepsy, 
defined as failure to bring seizures under acceptable control. 
Conclusions: A substantial percentage of children with new-onset epilepsy did not 
need treatment with AEDs. Chances of achieving a good outcome declined with 
subsequent treatment regimes. Not all children with recurrent seizures were 
suffering from intractable epilepsy; some had achieved acceptable control of 
seizures. 
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2.1 INTRODUCTION 
Treatment strategies in childhood epilepsy are not simple and unifonn. There 
is no universally applicable standard of treatment. Many unproven assumptions in-
fluence treatment decisions and may confound the perspective on important ques-
tions regarding the treatment of epilepsy. Publications which propose an algorithm 
of treatment in childhood epilepsy disagree on many issues. A basic point of discus-
sion is which children with seizures should be treated. It has been suggested that 
children with a first single seizure should not be treated, but also children with few 
or minor seizures may not need treatment with antiepileptic drugs (AEDs).21.H·9;31t is 
not known what proportion of children can safely be left without treatment. \Nhen 
treatment is considered appropriate, only global guidelines arc available to aid AED 
selection, although physicians may hold strong individual opinions.lc\" Specific 
recommendations for treaUllent are only given for some specific seizure types, like 
absences, infantile spasms, myoclonic or atonic seizures. ll8. There is no evi.dence 
which indicates how to treat patients who fail to respond to an adequate first AED 
regimen, although 1110st authors agree that for first- and second-choice therapy, 
mono therapy is generally preferable to poly therapy. 3~.3Q.-I6.QI The usefulness of poly-
therapy, the correct moment to initiate it, and with which combinations of AEDs, 
arc still matters of opinion rather than of comparative evidence. 3.3e. At some point, 
when a number of AEDs have failed to provide complete control of seizures and 
when the consequences of seizures are not acceptable, the epilepsy can be classified 
as 'intractable'. However, many different definitions to identify children with 'in-
tractable epilepsy' are being used. Most researchers H.W use operational criteria only 
based on seizure frequency or lack of remission. The essence of the concept of'in-
tractable epilepsy' is, however, failure to bring seizures under acceptable contro1. IQ)<l 
In the Dutch Study of Epilepsy in Childhood (DSEC), a large prospective 
multicenter hospital-based study on the prognosis of newly diagnosed chilclllOOd 
epilepsy, the child neurologists were allowed to choose the medical treatment they 
considered the most appropriate for any particular child. The following options 
were available: 1. No medical treaUnent. 2. Monotherapy with several first-line 
AEDs, preferably valproate or carbamazepine. 3. Combined therapy with first- and 
second-line AEDs. 
It is the primal)' purpose of this paper to audit the treatment strategies chosen 
by the participating neurologists. VVe were interested in the following questions: 
How many children with epilepsy are not treated with AEDs? How docs the selec-
tion between first-choice AEDs relate to seizure type? \Vhich strategies are chosen 
in case of failure of the first AED? Can we identify children who are not suffering 
from 'intractable epilepsy' despite the lack of a substantial remission from seizures? 
--12---
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2.2 METHODS 
2.2.1 Setting 
2.2.2 
2.2.3 
The Departments of Child Neurology of one children's hospital, one general hos-
pital and two university hospitals in The Netherlands participated in the OSEe. 
Children were treated by one of four child neurologists (HS, WFMA, OFB, 
ACBP). 
Patients 
Consecutive new referrals, aged 1 month to 16 years, who had had two or more 
idiopathic, cryptogenic or remote symptomatic seizures were included. We ex-
cluded children with neonatal seizures only, acute symptomatic seizures, chil-
dren referred from another hospital (to avoid selection bias towards unusually 
severe cases), and children with a history of epilepsy or treatment with AEDs 
(except for neonatal or febrile convulsions). 
A diagnosis of epilepsy (two or more unprovoked seizures) was made by a 
committee of child neurologists (HS, WFMA, OFB, ACBP), using predefined di-
agnostic criteria. Seizures were categorized according to the 1981 ILAE c1assifica-
tion. 1B In case of multiple seizure types, classification was based on the most 
troublesome seizures. Epilepsy was classified according to the 1989 ILAE criteria, 
two years after intake.29 Children were followed at regular intervals for at least 
two years until the endpoint of the study. 
Treatment 
The neurologists were free to decide when to start treatment with an AED, and 
the time between intake and start of treatment was noted. A delay in treatment 
was defined as treatment initiated more than 3 months after intake into the 
study, because a short delay could often be attributed to diagnostic or uninten-
tionallogistic causes. Any marketed AED was available for initial and subsequent 
treaUnent, but it was agreed to use valproate or carbamazepine as principal first-
choice AEDs and to use mono therapy as the first regimen. Poly therapy was to be 
selected only when at least two AEDs had failed as lllonotherapy. When poly-
therapy was considered appropriate, several first- and second-line AEDs could be 
combined. Initial medication and subsequent changes were noted on follow-up 
questionnaires. 'Poly therapy' was defined as the concurrent use of two or more 
AEDs for more than one month; hence, a short overlap between two AEDs when 
one was gradually being replaced by another was not considered poly therapy. 
Temporary poly therapy for status epilepticus or an episode of ACTH treatment 
in combination with a conventional AED were not included in the analysis as 
poly therapy. An AED regimen was considered to have failed when it was rc-
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placed by a new AED or new combination of AEDs. In some children, when 
seizures were quickly and completely controlled, AED treatment was successfully 
discontinued during the follow-up period. These children were analyzed as if 
they were still 011 the discontinued AED after two years. Results of discontinua-
tion of AEDs will be published separately. 
Outcome 
'vVe analyzed the number of children not receiving any AED two years after in-
take and until the endpoint of the study. For children receiving AEDs, we noted 
how many subsequent treatment regimens had been given after two years of 
medication, and the number using ll1ono- and poly therapy. 'vVe also studied the 
relationship between seizure type and the selection of the first AED, and the rea-
sons for failure of the first AED. 
The duration of any remission from seizures was calculated from seizure 
calendars. Outcome with respect to seizure control was classified as 'good' (ter-
minal remission, as measured two years after the start of medication, more than 
12 months), 'fair' (temlinal remission between 6 and 12 months) or 'poor' (ter-
minal remission less than 6 months). When seizure calendars were considered 
unreliable, e.g., when pseudoseizures were intermingled with genuine seizures, 
when patients were lost to follow-up or when follow-up was less than 2 years 
after the start of medication, the outcome classification was discarded. In patients 
without medication, we assessed outcome two years after inclusion. Children 
with poor compliance were included in the analysis because the reasons for non-
compliance were not systematically registered and may have included lack of ef-
ficacy or intolerable side-effects; and because their outcome was not different 
from the outcome of the entire group (Arts et ai, submitted). 
To identify cases with 'intractable' epilepsy, we selected children in WhOlll-
despite treatment with AEDs- the 'longest remission ever' was less than 6 months 
during the entire follow-up period. \oVithin this group of children, we identified 
children who had received no new AEDs or increased dosage of AEDs during the 
last six months of follow-up. \Ve explored the possibility that control of seizures 
had been 'acceptable' in these children. For this purpose, we issued a ren'o-
spective questionnaire to the child neurologist in charge. The neurologist was 
asked whether, in his opinion, the child had achieved 'acceptable control' during 
the last six months of follow-up and, if so, whether this was due to a low seizure 
frequency or acceptable severity of seizures or to other reasons. \\Then seizure 
control was found not to be 'acceptable', the physician could confirm whether he 
had decided not to change the AED regimen because there were no reasonable 
alternatives left, or state other reasons. 
--14 ---
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Data analysis 
This is a primarily descriptive study. All data were analyzed using SPSS. Tests of 
significance of differences between groups were made using Chi-Square analysis. 
2.3 RESULTS 
During the 4-year intake period, 494 children who had had two or more unpro-
voked seizures were included. Median age at intake was 5.5 years (range 0.1-
15.8); 239 (48%) were boys. 254 (51 %) children were referred by a general 
physician, 125 (25%) by a pediatrician, 78 (16%) came directly to an emergency 
department and in 37 (8%) the referral pattern was unknown. 
Seven children 0%) were lost to follow-up (2 without treaunent, follow-up 
1 and 18 months, respectively; 5 on AED treatment, follow-up 3 months after 
start of medication in 2 children, and 12 months in 3 children). Three children 
died during the follow-up period, all of whom were receiving AEDs. An addition-
al 17 children were not followed for two years after the initiation of medication, 
because treatment was not started immediately after intake and hence they 
reached the endpoint of the study (August 1994) before they had been receiving 
medication for two years. Treatment analysis included these 17 children as if 
they had been followed for two years after treatment. However, they were not in-
cluded in the classification of outcome with respect to remission. 
The classification of epilepsy and seizures of the total cohort are listed in 
Table 2.1. Figure 2.1 shows the time between intake and start of any AED treat-
ment for the entire group. Median time after intake until treatment was 18 days 
(25-75 percentiles: 2-58 days). 
100 
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Figure 2.1 Time between intalw into the study alld start oj Clny antiepilejJtic drug 
treatll1ellt oj a co/lOrt oj childrell with lIewl)' deVeloped epileps)' (N=494 . 
--- 15 ---
AUDIT OF CUNICAL PRACTICE 
2.3.1 Untreated children 
2.3.2 
2.3.3 
Three months after intake, 142 (29%) children were not receiving AEDs. Two 
years after intake, 82 (17%) had still received no AED treatment. SevCIlty-eight 
(16%) children were not given any AEDs until the endpoint of the study. There 
was no significant difference in the overall epilepsy classification of children 
treated and not treated with AEDs, if unclassified cases were omitted (sec Table 
2.1). The untreated group included more children with 'other/unclassified' 
epilepsies and fewer children with 'cryptogenic ancUor symptomatic' generalized 
epilepsies than the treated group. There was a significant difference in seizure 
classification between the untreated and treated group (P~.05, see Table 2.1). 
The untreated group included more children with generalized tonic-clonic 
seizures and fewer with absences and other/not classified seizures (including my-
oclonic and atonic seizures). After two years, 73 untreated children showed the 
following outcomes: good in 58 (79%), fair in 3 (4%), poor in 12 (16%). 
Outcome could not be classified in 5 children. 
First-choice AED 
In accordance with our protocol, the first AED regimen was monotherapy in all 
cases. Table 2.2 lists the AEDs used as first-choice m.edication and the distribu-
tion of seizure types per AED. 88% of the children were initially treated with val-
proate or carbamazepine. 
Two years after the st.:lrt of treaunent, 250 (60%) children were still using 
the first-choice AED or had successfully discontinued it. Their outcomes with re-
spect to terminal remission are listed in Table 2.3. 
Failure of the first AED: subsequent treatment strategies. 
Of the 416 children who were treated with AEDs, 166 (40%) did not respond 
successfully to their first AED and used at least one alternative or additional 
AED. Reasons for failure of the first AED were recurrent seizures in 115 (28%) 
children; intolerable side-effects in 47 (11%) (with or without recurrent 
seizures); initial misc1assification of seizures in two; and unknown in two chil-
dren. Intolerable side-effects were allergic rashes in 15 (4%) children, 14 of 
whom were on carbamazepine 00% of all children who started with carba-
mazepine) and one on valproate; and other side-effects in 32 (8%), without 
substantial differences between AEDs. 
Table 2.3 shows that there was a clear negative association between the num-
ber of AED regimens tried and the chance of achieving a substantial remission. 
When three regimeIlS had failed, the chance of achieving a good outcome \vith subse-
quent regimens was only 10%. None of the children who had experienced failure with 
four or more AED regimens achieved a good outcome during the follow-up period. 
--- 16 ---
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Monotherapy/polytherapy 
Two years after the start of treatment, 334 (80%) of the 416 children receiving 
AEDs were treated with mono therapy and 82 (20%) with poly therapy. 
Poly therapy regimens consisted of two AEDs in 65 and three AEDs in 17 chil-
dren. 25 (30%) of the 82 children who received poly therapy had tried two 
monotherapy regimens. 
In total, 42 different AEDs or combinations of AEDs were used. The most 
frequently chosen combinations of AEDs were valproate with a benzodiazepine 
(clobazam was used morc than other benzodiazepines), valproatc with carba-
mazepine, and valproatc with ethosuximide. 
The classification of epilepsy of the 82 children on poly therapy at two years 
included a greater proportion with symptomatic!cryptogenic epilepsies as com-
pared to the group as a whole. Of the children with localization-related epilepsy, 
two wcrc classified as idiopathic and 29 as symptomaticlcryptogenic, and of 
those with generalized epilepsy, 17 were classified as idiopathic and 34 as 
symptomatic/cryptogenic. 
'Acceptable control' despite lack of a remission 
Fifty children had a 'longest remission ever' ofIess than 6 months despite treat-
ment. Hence, these children were suffering from 'intractable epilepsy' when this 
concept was defined as lack of remission alone. Of these 50 children, 32 had had 
adjusunents in their AED regimen during the last six months, suggesting that 
their seizure control had not been 'acceptable'. Eighteen children had had no 
change in their AED regimen (including increased dosages) during the last 6 
months of follow-up. Thus, we explored whether seizures had been 'acceptably 
controlled' despite the lack of a substantial remission in these 18 children. 
In response to our retrospective questionnaire concerning these 18 chil-
dren, the neurologists stated that medication was not changed because 'ac-
ceptable control' was achieved in 15 children, and because there were no further 
options for treatment in 3 children. They attributed 'acceptable control' to low 
seizure frequency in 12 ancVor low seizure severity in 8 children. The reported 
lack of alternative options was attributed to poor compliance in one child. One 
child with 'acceptable control' had few and mild seizures, but seizures were also 
often self-induced and this was an additional reason for not having adjusted the 
medication further. 
--- \7 ---
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2.4 COMMENT 
2.4.1. 
2.4.2 
This analysis of data of the Dutch Study of Epilepsy in Childhood (DSEC) pro-
vides a descriptive overview of the treatment strategies chosen by the neuro-
logists in charge. Our cohort comprised children with all seizure types and a 
broad variety of epilepsies and epileptic syndromes, as seen in four primary re-
ferral centers. 
No AED treatment 
All children in the study had had at least two unprovoked seizures. Nevertheless, 
treatment was initially withheld in 29%, and this approach could be continued in 
more than 50% of these children. In 17 % no AEDs were given during a follow-
up of two years after intake in the study, and only 4 children received their first 
AED more than two years after inclusion. Because there is no evidence that AEDs 
influence the natural course of epilepsy or that untreated epilepsy commonly 
evolves inLa a progressive disease,37 AED treaUnenl might essentially be pal-
liative. it has been suggested that most children with epilepsy should receive an 
AED only when the impact of recurrent seizures outweighs the possible adverse 
effects of medication.2!.t~.93 Our data provide a minimum estimation of the propor-
tion who may not need AEDs, because in most children we have not tried La 
withhold treatment. \\'e know of no other comparable data indicating how many 
children with epilepsy may not need treatment with AEDs. Our data suggest that 
both parents and neurologists of the children in our sample have reservations 
about starting medication carlyon in the disease, but we had no detailed infor-
mation about their motivation not to start treaUnent in individual cases. There 
were no adverse events such as seizure-related serious injuries or deaths in the 
unu-eated group. The high percentage of untreated children achieving a terminal 
remission of more than one year points to a selection process during follow-up. 
A group of children with a relatively favourable prognosis for spontaneous remis-
sion was not treated initially, and most children who nevertheless had one or 
more recurrences were given medication at a later date. 
First-choice treatment 
The first-choice AED was retained for two years in 250 of 416 children (60%) 
and resulted in a terminal remission of> I year in 63%. in two randomized stud-
ies of children with epilepsy the allocated AED was successful in a somewhat 
larger percentage. I (\l.1l1 However, an important difference between our population 
and those of the randomized studies is that we have included children with all 
seizure types, rather than only children with simple, complex partial or general-
ized tonic-clonic seizures. This difference clearly pertains to the choice of AED 
--- 18 ---
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therapy and La the prognosis. 
In the study protocol, valproate and carbamazepine were chosen as the 
main AEDs for initial treatment; a choice based on considerations of toxicity and 
pharmacokinetics. At the time we embarked on our study, phenobarbital was al-
ready recognized as a relatively toxic AED, and in the present investigation it was 
used only as a first AED in exceptional cases. Phenytoin has a more complex 
phanllacokinetic profile than carbamazepine or valproate, and may be associated 
with more long-term side-effects. 
vVe noted a trend to select valproate for children with generalized seizures 
and carbamazepine for children with partial seizures. This is probably common 
clinical practice 3.3<>.118 supported by the results of one comparative trial in adults.71 
Recent comparative studies in adults ';3,92 and children 1(\t.1.1I2 showed no significant 
differences in efficacy between valproate and carbamazepine for generalized or 
partial seizures, but these were published after the intake period of our study. 
"Ve included children with seizure types associated with severe sympto-
matic epilepsies, like infantile spasms or atonic seizures. In the majority of cases 
where a benzodiazepine, ACTH or vigabatrin was chosen as the initial treatment, 
children had one of these seizure types; many of them had the "Vest or Lennox-
Gastaut syndrome. Vigabatrin was registered in The Netherlands in 1991, and 
only children who were included after this date could be treated with this AED. 
Furthermore, we included children with absences. For this seizure type, 
valproate and ethosuximide are probably equally effective and most other AEDs 
are ineffective. Valproate was used in almost all children with absences as the 
first AED, and ethosuximide was used as the second AED in case of failure of 
valproate. Some authors have recommended ethosuximide as first-choice AED 
for childhood absences because it is not associated with the possibility of severe 
hepatotoxicity.H.~b.II8 vVe had no occurrences of valproate-induced hepatoxicity in 
our study. The advantage of valproate as first-choice AED in absences is its effi-
cacy against tonic-clonic seizures, which may be associated with absences. 
Failure of the first AED 
The first AED failed in 166 of 416 treated children (40%). Recurrent seizures 
were the main reason to replace the first AED. On the whole, intolerable side-ef-
fects were relatively rare (11% of first AEDs). Verity et at reported intolerable 
side-effects related to the randomized AED in about 13% III and de Silva et al in 
about 4%.)('" However, many side-effects to AEDs are subjective and, because a 
standardized assessment in this and most other studies was lacking, results with 
respect to such side-effects are difficult to compare. 1t often remains unclear why 
a side-effect is considered 'intolerable'. In our study, allergic rashes occurred in 
4% of the first AED regimens and were strongly associated with the use of car-
--- 19 ---
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bamazepine. Others have suggested that snch allergic reactions to carbamazepine 
are relatively rare in children compared with adults. m\!l2 y\le noted a prevalence 
of allergic rashes associated with the use of carbamazepil1c comparable to that 
found in adult studies.12m 
After failure of the first AED, alternative or additional AEDs were pre-
scribed in about 40% of the children. In two randomized studies, 29%ll\l to 34%!ll 
of the children received alternative or additional AEDs. The inclusion here of 
epileptic syndromes with a poor prognosis may explain that our percentage of 
first AED failures was higher. 
When designing our protocol, we agreed, whenever possible, to try two 
monotherapies before switching to poly therapy. There is no experimental evi-
dence regarding the optimal number of mono therapy regimens before the patient 
can be considered as a candidate for poly therapy 1l\ but most authors recommend 
exhaustive ~o or at least two 3.30 1110notherapy trials of first-line AEDs before initi-
ating poly therapy. In our study, however, the percentage of children receiving 
poly therapy who had first tried two first-line AEDs as l11onotherapy was only 
30%, despite our initial intentions. The use of poly therapy as the second step in 
treatment was associated with poor control of seizures and symptomatic epilep-
sies like the \Vest or Lennox-Gastaut syndrome. These children may have re-
ceived poly therapy already after failure of the first AED, because it is well known 
that combined medication, e.g., valproate and a benzodiazepine, is often neces-
sary to achieve acceptable control in such epilepsies.M 
In our study, a terminal remission of at least one year was achieved in 56 of 
the 166 (34%) children who failed on the first AED regimen. After failure of four 
AED regimens, a remission of more than one year was not achieved during our 2 
year follow-up. In the first VA-multicenter study, failure of the first AED was fol-
lowed by 'successful' alternative AED therapy in a somewhat higher percentage 
(46%) of adult patients!' 
Acceptable control and intractable epilepsy 
'Intractable epilepsy' is probably best defined as a subjective concept that implies 
failure to bring seizures under acceptable contropq, and what exactly is accept-
able depends largely on the individual. Clearly, it is difficult to translate such a 
definition into scientific data. In our study, 50 of 416 children treated with AEDs 
achieved no substantial remission, but our data suggest that 'acceptable control' 
was nevertheless achieved in 15 of these children. Thus, only 35 children (7% of 
the cohort) were really suffering from 'intractable epilepsy'. 
vVe have not been able to study directly the reasons for certain choices re-
garding treatment; more specific assessments of the impact of seizures and side-
effects of AEDs in individual cases would have been usefu1. Such data may also 
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be helpful in properly identifying children with intractable epilepsy. We have 
developed subjective parent-completed scales quantifying the severity of seizures 
and side-effects of medicatioll.16 In general, a broad outcome assessment, includ-
ing measures of quality of life, is relatively complex compared to traditional mea-
sures, but will give better insight into the strategies chosen in the treatment of 
childhood epilepsy and their results. 
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Table 2.1. Epilepsy and seizure classification 
Number of children 
Epilepsy classification 
10 caliza lion -related 
- idi0l'atJlic (with age-rdatcd ollset) 
- symptomatic 
- o),ptogCllic 
generalized 
- itliopatllic (with age-related OIlSI't) 
- CI),ptogcllic lIml/or symptonwtic 
other/not classified 
Seizure type 
generalized tonic-clonic 
complex partial 
simple partial 
absences 
other/not classified 
Total group 
494 [1001 
1941391 
30 (6J 
71 (14J 
93 (19J 
279 1561 
205 £42J 
74 [15J 
21 HI 
297 [60] 
491101 
26 IS] 
61 1121 
61 1121 
Untreated 1 
78 (100) [161 
32 (41) [61 
7 (9) (1] 
9 (12) [2J 
16(21)[3J 
40(51) 18] 
36 (16) [7] 
4 (5) J1] 
6 (8) III 
57 (73) [121 
7 (9) III 
5 (6) II] 
5 (6) III 
4 (5) III 
( ) column percentages, [! percentages of the total group (494 children). 
1 until the endpOint of the stud}', minimal follow-up of two years 
Treated 1 
416 (100) [841 
162 (39) [33] 
23 (6) [5J 
62 (15) [13J 
77 (19) [16J 
237 (57) 148] 
169 (41) [34J 
70 (17) J14J 
15 (4) [31 
240 (58) [491 
42 (10) 191 
21 (5) 14] 
56 (14) Illi 
57 (14) Illi 
Comparing treated and untreated children: differences in epilepsy classification were not Significant; 
differences in seizure type were Significant (P", .05). 
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Table 2.2. First AED regimen: selection of AED and seizure type 
AED Number of children Seizure type 
GTe CPS SPS Abs Other 
Valproate 221 (53) 122 (51) 14 (33) 5 (24) 53 (95) 27(47) 
Carbamazepine 147 (35) 100 (42) 24 (57) 16 (76) 1(2) 6 (I!) 
Benzodiazepiues 13 (3) 2 (I) 1 (2) 0(0) 0(0) 10 (18) 
Phenytoin 12 (3) 8 (3) 2 (5) 0(0) 1 (2) 1 (2) 
Phenobarbital 9 (2) 7 (3) 0(0) 0(0) 0(0) 2 (4) 
ACTH 60) 0(0) 0(0) 0(0) 0(0) 6 (ll) 
Ethosuximide 4 (1) 1 (0.5) 1 (2) 0(0) 1 (2) 1 (2) 
Vigabatrin 4 (1) 0(0) 0(0) 0(0) 0(0) 4 (7) 
Total 4161100J 240 [58J 42 [IOJ 21 [5J 56 [14J 57 [14J 
( ) column percentages, [J row percentages. AED= antiepileptic drug. Classification of seizures was based on ILAE guide· 
lines. l ' GTe" (primary or secondary) generalized clonic~tonic seizure. CPS= complex partial seizure, SPS", simple panial 
seiZ1lre, Abs= absence, Other", other or unclassified seizure types. 
In case of more than one seizure type, the most troublesome type is listed. 
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Table 2.3. Children receiving AEDs: Retention in subsequent treatment regimens 
and outcome with respect to terminal remission two years after the 
start of medication 
Treatment 
Monotherapy Polytherapy 
Outcome 
Total Good Fair Poor Not classified 
AED regimen 
1st 250 1100%1 o [Of 250 (5 I) 144 [63] 35 [IS[ 49 [22] 22 
2nd 74 [80] 19 [20] 93 (19) 45 ]51] 11 [13] 32 ]36] 5 
3,d 5 [171 24 [83] 29 (6) 8 [29] 6 [2l] 14 [50] 
4th 4 [13] 26 [87[ 30 (6) 3 [1O[ 3 [1O[ 24 [80[ 0 
5th 1 fIll 8 [89[ 9 (2) 0[0] 0[0] 9 [100] 0 
6th o [O[ 4 [100] 4 (1) o [O[ o [O[ 4 [100] 0 
7th 0[0] 1 [100] 1 (0) o [O[ 0[0] 1 [100[ 0 
Total AED 334 [80] 82 [20[ 416 (84) 200 [52] 55 [14] 133 134[ 28 
() column percentages, II row percentages. Outcome criteria: good=terminal remission> 12 months during two years of 
follow-up after the start of medication, fair=tenninal remission> 6 and < 12 months, poor=:tenninal remission < 6 
months. AED=antiepileptic drug. 
Numbers and percentages of children in treatment regimes include 8 children who were followed < 1 years. Outcome 
was not classified in children who were lost to follow-up or followed < 2 years or when seizure calendars were unreli-
able. Outcome percentages only refer to children who could be evaluated. 
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3.0 ABSTRACT 
During the past decade, several scales have been developed to improve the 
assessment of outcome in epilepsy. These scales were developed for adults and 
their reliability, validity and usefulness have been established. However, there is 
also a need for alternative measures of outcome in childhood epilepsy, especially a 
measure of seizure severity (55) and measures pertaining to quality of life (QoL). 
Four of these adult scales are reviewed and compared to examine their 
applicability in childhood epilepsy. Two important methodological differences 
are discussed: a) patient self-report vs. physician-based scales, and b) generic vs. 
disease-specific scales. QoL in epilepsy is briefly reviewed. Severity of seizures 
and side-effects are relatively neglected areas of importance to QoL in epilepsy. 
The existing scales for adults are not appropriate for children in their pre-
sent form. Some specific methodological issues, which are relevant for the devel-
opment of scales for children with epilepsy, are subsequently discussed. New 
scales pertaining to physical and psychosocial aspects of QoL in childhood 
epilepsy are being developed. In the near future, data on their reliability, validity 
and usefulness will become available. A combination of scales focusing on specif-
ic aspects of QoL, including 55 and severity of side-effects, and more traditional 
clinical data may provide a more complete assessment of outcome in childhood 
epilepsy. 
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3.1. INTRODUCTION 
Traditionally, outcome assessment in epilepsy has pertained to seizure fre-
quency (SF). The limitations of this approach are obvious. Clearly, there are 
more variables that may be relevant for patients with epilepsy. In the past dec-
ade, several health measurement scales have been developed to improve assess-
ment of outcome in epilepsy H.32,t\.\!16. These alternative outcome measures were 
developed for adults with epilepsy. As such, they are probably inappropriate for 
children 93. As epilepsy in childhood is relatively common and not always easy to 
control, the need for improvement of traditional measures of outcome for chil-
dren with epilepsy is well recognized 11.3". We studied the relevant literature on 
outcome measures in epilepsy, as a starting point for the development of scales 
for childhood epilepsy. Furthennore, we explored the specific problems relating 
to the development of outcome measures for childhood epilepsy. Although a 
wide spectrum of clinical and psychosocial problems applies to patients with 
epilepsy, this paper will only address the clinician's primary concerns in epilepsy 
treatment: seizures and adverse effects of medication. 
Drug treatment will succeed in controlling seizures within a short period of 
time in about 70% of new onset patients 6,7,19.11. In the remaining 30%, reasonable 
regimens fail to bring seizures under complete control. In 10-15 %, chances of 
remission are extremely poor 19,60; these patients are referred to as 'intractable' 2". 
In clinical practice, the aim in such cases is La find the optimal balance between 
seizure suppression and adverse effects of medication. Thus, a careful and com-
plete assessment of the frequency and severity of seizures, as well as the preva-
lence and severity of side-effects, is necessary. 
3.2 SCALES TO MEASURE THE CLINICAL SEVERITY OF EPILEPSY IN 
ADULTS 
A comparison of four scales that have been developed to measure the sever-
ity of seizures and adverse effects in adult epilepsy demonstrates qUite clearly the 
different strategies in the approach to outcome assessment in epilepsy. \Ve select-
ed these scales because they are well described in the literature. 0) Two phys-
ician-based scales will be described. (2) Two patient-based scales will be intro-
duced which have been incorporated in quality of life (QoL) studies. The first 
three scales predominantly contain items which are specific for epilepsy, the last 
scale is a more generic measure. These differences in methodology will be dis-
cussed in subsequent sections. 
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Veterans Administration (VA) Rating Scales for Seizure Type and 
frequency, Neurotoxicity and Systemic Toxicity (VA scale) 
The VA scale provides a composite score intended to represent 'the overall 
effect of seizures and toxicity from medication on the QoL of a patient' 32. It rc-
lates to SF, seizure type and severity, and severity of antiepileptic drug (AED) 
toxicity. This physician-based scale, developed in 1983 by Cramer et al., was 
used in an influential comparative trial of four AEDs 73. A slightly modified scale 
has been validated in a Dutch population with epilepsy by Wijsman et al. "'. This 
modified scale has been used for audit studies in adult epilepsy ({>.ll~. 
The design of the VA scale lor Seizure Type and Frequency reflects the idea 
that the three most common seizure types in adults are not equally severe. 
Separate subscales provide ratings for generalized tonic-clonic seizures, complex 
partial seizures and simple partial seizures. The combination of type and fre-
quency gives the basic score, with subsequent modifications for the presence of a 
useful aura, an avoidable precipitating factor, 'subtherapeutic' AED levels and 
specific patterns of seizures. Since seizure classification is a major factor in the 
determination of seizure severity (55) in this scale, it has certain limitations, as 
discussed below (see Section 4.1). The VA scale has no rating for such gener-
alized seizure types as absence and atonic seizures, which are rare in adults but 
not in children. 
The VA scale takes the perspective of the medical-professional and does not 
measure patient perceptions. This causes concern about the relevance of the 
scale and the validity of the complex scoring system. For example, in the Sys-
temic Toxicity Scale the same score is given to 'reduced platelet count « 75000)' 
and to 'frequent vomiting'. As far as the patient is concerned, these are problems 
with an entirely different impact. As such, the VA scale is not adequate for 
assessments of QoL as we would define it today (sec Section 3.1). 
Chalfont SS Scale 
This scale was designed by Duncan and Sander in 1991 and measures only 
SS -\<1. It is completed by the physician, preferably during an interview with the 
patient and an eye-witness of the seizures, as detailed information about the 
seizures is requested. The physician has to make a medical-professional dis-
tinction between different seizure types in a patient. As in the VA scale, separate 
columns provide separate severity scores per seizure t)1Je. Individual item scores 
are modified according to the relative frequency of occurrence in a seizure type 
(e.g. when incontinence occurs in 25% of seizures, the incontinence score is 
quartered). 
The Chalfont scale aims -to measure aspects of SS that can be recorded 
objectively. Although the scale and wcightings were based on interviews with 
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both patients and their close relatives, it does not necessarily reflect the individ-
ual patient's opinion. 
To our knowledge, the Chalfont scale has not been validated in children. 
Liverpool SS Scale 
This epilepsy-specific scale was developed to measure the ('subjective') 
severity of seizures as perceived by the patient, although it includes some 'objec-
tive' items n. The scale consists of two suhscales: perception of control and ictal 
and postictal events. Most items use a simple subjective four-point response 
scale, ranging from 1 (the patient perceived that aspect of the seizure to be no 
problem) to 4 (a severe problem). The patient may choose to complete different 
columns for his/her 'major' and 'minor' seizures. There is increasing evidence 
that this scale is reliable, valid and useful as an outcome measure in a clinical 
trial 14,10}, It has been included in a multidimensional model for QoL in epilepsy 
developed by Baker and colleagues Il,H, A similar patient-based adverse event 
profile has been developed by the Liverpool research group (Baker et aI, written 
communication), 
Although these scales reflect the individual patient's perception, both the 
Liverpool SS Scale and the Adverse Events Profile agree well with the clinician's 
paradigm of the severity of epilepsy ~1, As these are self-report scales for adults, 
they would have to be modified to be applicable in a childhood population. 
Epilepsy Surgery Inventory (ESI)-55 
The ESI-55 was developed by Vickrey and colleagues in 1992 ''". Like the 
Liverpool scales, the ESI-55 is a subjective patient-based scale. This self-report 
scale was developed for studies assessing the outcome of epilepsy surgery in 
adults. It consists of a generic core (the RAND 36-lIem Health Survey) with 
additional items, providing an epilepsy-specific supplement. The items about 
physical function and pain do not specifically address the consequences of seizu-
res or antiepileptic medication. \Vhen compared to the Liverpool scales, the ESI-
55 is a more generic measure of QoL and its relation to epilepsy-specific clinical 
variables, like SS and severity of adverse effects, is not as direct as·in the 
Liverpool scales. The ESI-55 has been applied to evaluate seizure-based outcome 
systems from studies addressing the outcome of epilepsy surgery 117. 
Because the ESI-55 was designed for patients with a severe form of epilepsy 
who are candidates for epilepsy surgery, it may not be valid for less severe forms 
of epilepsy. For this reason, the ESI-55 was expanded for broader application as 
the QoL in Epilepsy (QOLlE) scale ". In their present form, as self-report scales 
for adults, they are not appropriate for children with epilepsy. 
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3.3. DEFINITIONS AND BASIC DIFFERENCES IN METHODOLOGY 
The previous section has shown that there are important differences be-
tween existing health measurement scales for seizures and adverse effects of 
AED. Not surprisingly, none of these scales seems directly suitable for use in 
childhood epilepsy. However, they illustrate some important differences in 
methodology. 
First, it seems appropriate to define two terms associated with assessment 
of outcome of chronic disorders: QoL and clinimetrics. Two basic methodologi-
cal differences in the presented sample of scales are subsequently discussed. 
3.3.1. QoL 
Health-related QoL (or perceived health status) refers to a scientific analy-
sis of the functional outcome of a disease and its treatment in a patient %, The 
goal is to quantify patient's perceptions as valid and reliable data 11, According to 
Schipper et al., the questions included in the assessment may be drawn from the 
experience of patients, relatives and health care providers, but they should be an-
swered froIll the patient's perspective %, Some authors, however, take a more re-
strictive - patient-centred - view H. Karnofsky and colleagues were the first in the 
literature to demonstrate the importance of assessment of the effects of disease 
on a patient's functional status 61, The formal use of the term QoL developed later 
and its definition is still - to some extent - a matter of debate. 
QoL is essentially a multidimensional concept, including physical, psycho-
logical, social and economic domains %, It is widely recognized as an important 
outcome measure in chronic disease I, The major drawback in the use of QoL 
assessments, is the lack of consensus on how it should be measured -H.~8 and the 
complexity of most attempts to measure it. 
3.3.1.1. QoL and Epilepsy 
Epilepsy is a relative latecomer in the field of formal QoL studies 12.~~. A 
great deal of past psychosocial research on the impact of epilepsy might be 
appropriately termed 'QoL -research' 5-1,9), QoL in epilepsy has been reviewed 
elsewhere )t,7l,95,lll3, From these reviews it becomes clear that the physical domain 
has been neglected as compared to the psychosocial domain, Many studies claim-
ing to report QoL have only addressed psychosocial issues. Hennann identifies 
symptoms and functional status as underinvestigated areas of QoL in epilepsy H. 
As QoL is the ultimate outcome of medical treatment of any chronic disor-
der, there is no doubt that it is relevant in epilepsy and should be incorporated 
in trials comparing treatment regimes 3335.75.121, 
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Clinimetrics 
Clinimetrics refers to the use of rating scales which transform c1 inical data 
into a score. This allows the summation of different medical variables and, thus, 
facilitates statistical comparisons of a patient's status and the assessment of 
change after treatment H. This does not imply that the clinician is the only 
source of information. Clinimetric tools usually relate to severity of disease in 
medical terms, but can be a part of QoL research, when they quantify clinical 
data from the patient's perspective: a clinimetric approach to assessing QoL in 
epilepsy JI. 
Methodological issues 
A comparison of the scales in Section 2 indicates that there are important 
methodological differences between them. At least, we can make a distinction 
along two axes. 
(1) Physician·based vs. patient-based scales (2.1 and 2.2 vs. 2.3 and 2.4). 
(2) Epilepsy-specific vs. generic scales (2.1 to 2.3 vs. 2.4). 
Clearly, two questions are of importance: 
- Who determines the clinical severity of disease: the doctor or the patient? 
- When should we use disease-specific scales and when a (more well known) 
generic profile? 
3.3.3.1. Who determines disease severity? 
Many authors agree that the patient is the most important authority regard-
ing the effects of disease on his/her life ll.ll'1. At least, doctors and nurses are not 
able to assess overall QoL of their patients in a meaningful and reliable way ll'2. 
This favours the assessment of subjective disease severity as perceived by the pa-
tient and QoL assessments are based on this principle. The openly subjective na-
ture of QoL assessments, however, is a source of unease among some investiga-
tors %. In the opinion of some authors, physician-based scales are more 'scienti-
fic' than scales reflecting patient's perceptions 18. 
Perhaps, a sharp division between 'patient-based' and 'physician-based' 
scales is too artificiaL Any health measurement scale reflects patients' as well as 
doctors' opinions both in the development and selection of the scale a.s well as in 
the completion of the scale in an individual patient's case. 
3.3.3.2. Generic and specific scales 
Disease severity can be assessed with generic scales which are broadly ap-
plicable across different diseases and populations, or with disease- or popu!ation-
specific scales H.-N.H87. A clear advantage of many generic scales is that they are 
well validated. This is especially important, sillce for most health measurement 
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scales there is no 'gold standard' to assess their validity in a simple way. 
However, using such generic scales, one can easily miss important prob-
lems that relate only to a specific condition. If one focuses more accurately on a 
specific disease or population, this will result in increased responsiveness of a 
scale ~9. As epilepsy is not an 'average' disease, we agree with others that at least a 
fair amount of epilepsy-specific items should be included in any scale developed 
to assess treatment effects in clinical trials concerning epilepsy 103. 
3.4. EPILEPSY-SPECIFIC SCALES: SEIZURES AND SIDE-EFFECTS 
3.4.1. 
3.4.2. 
As the severity of uncontrolled epilepsy depends to a large extent on the 
frequency and severity of seizures and side-effects of AEDs, these variables 
should be addressed adequately in epilepsy-specific scales. 
SF and type 
Most clinical trials in intractable epilepsy are based on an assessment of 
change in SF. However, there is no consensus on how a change in SF should be 
measured or reported. A large number of different outcome systems, typically 
classi~ring patients into categories relating to SF, is used 8.32.111. For some seizure 
types, reports of SF may be unreliable as they are difficult to quantify without 
sophisticated techniques H. 
The outcome systems used in most studies fail to recognize that the conse-
quences of seizures determine the number of attacks which an individual patient 
will tolerate. At least for patients with several 'minor seizures' a day, the absolute 
quantity of seizures may not be clinically relevant, nor would a reduction in SF 
of 50% be very significant 1~.~5JI7. 
Seizure type and severity 
SF is quite meaningless without at least information about seizure type. 
Clinicians will have some idea of the average severity of different seizure types. 
For example, seizure duration, an obvious indicator of S5, is related to seizure 
type NI.1l8. Loss of consciousness during a seizure influences both ~lassification 
and 55. However, the ILAE seizure classification 28 is not a com.plete·and sensitive 
indicator of 55 . 
• It lacks content validity for this purpose: many factors that intuitively are rele-
vant to 55, are not included: incontinence, injuries, postictal dysfunction etc . 
• I t lacks discriminative ability: within one seizure type, factors relating to severi-
ty may vary, e.g. a complex partial seizure lasting 15 s is less severe than a 
complex partial seizure lasting 8 min, despite identical classification. 
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• It is not adequately sensitive to change in 55: a change of SS can only be moni-
tored if it results in a change in classification . 
• It is not as practical as it might seem: especially, in the more complex child-
hood epilepsies seizure classification is not a simple matter \lS, 
In conclusion, for studies of uncontrolled epilepsy, a combination of a mea-
sure of SF and seizure classification is not sufficient. The development of a com-
plete seizure-based outcome system should include a specific measure of 55. 
In Section 2 we reviewed two scales, providing such a measure of 55: the 
Chalfont and the Liverpool 55 scales (Section 2.2 and Section 2.3, respectively). 
Both scales include to a large extent the same variables, as shown in Table 3.l. 
According to Cramer, the major problem inherent in assessing SS are de-
pendence on patient recall and reporting, and observer documentation 31. 
Timing, predictability and control of seizures 
The VA and Chalfont scales include modifying factors for timing andlor 
predictability. The Liverpool 55 scale has a subscale for this construct (Table 
3.1), although it is less reliable and sensitive than the ictal subscale 1115. The com-
mon idea is that some degree of predictability and control makes seizures less 
likely to cause injuries and perhaps less severe. 
Adverse effects of antiepileptic drug treatment 
At present, in most studies, reports of adverse effects are descriptive and 
lack quantification 67.71. Assessment of adverse effects is of great importance in 
epilepsy treatment k1.4:;.69. Considerations regarding adverse effects influence the 
selection of an AED regimen 5l.69,7J.IIl. Adverse effects are associated with high 
doses and the use of multiple AEDs 69,91. Thus, patients with uncontrolled seiz-
ures are at risk for adverse effects, as they are often prescribed high doses or a 
combination of AEDs 97, 
It is possible to classify adverse effects along different axes, such as relation-
ship to duration of therapy (early vs. late adverse effects) or relationship to dose 
(idiosyncratic vs. dose-dependent adverse effects) or by organ system k>. The most 
frequent adverse effects are dose-related, not dangerous and quite subjective ffl, They 
may come and go when the dose is changed or when the patient's tolerance to the 
drug changes -II. Therefore, an individual, subjective measure for these 'su.btle' ad-
verse effects seems useful. Clinically severe adverse effects are a rare and dear medi-
cal-professional problem and the patient's perception in such cases is less relevant. 
Behavioural and cognitive adverse effects are usually evaluated with standardized 
psychological tests 5.70,. As these psychological tests are not easily administered, 
especially in children, a more simple (screening) tool may be useful kl. 
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3.5. HEALTH MEASUREMENT SCALES IN CHILDHOOD EPILEPSY 
3.5.1. 
it is not surprising that health measurement scales developed for an adult 
population are seldom appropriate for children ". We concluded that the re-
viewed scales for adult epilepsy patients ill their present form are inappropriate 
for childhood epilepsy. Let us look at the reasons for this conclusion and at some 
specific issues relating to scales for children and childhood epilepsy. 
Who determines disease severity in children? 
Children are a problematic group for self-report scales. Self-report scales 
for children require separate scales at least for different age groups. Probably sex 
groups should be analyzed separately at different developmental stages, as during 
the school age period, girls may have relatively superior language and social 
skills 1'>2. All this makes it difficult to compare results. 
Second, any researcher developing a self-report scale for children should be 
aware of their structurally different way of thinking about disease ~}. A model of 
severity of epilepsy that makes sense to adults, may not agree with the ideas that 
children have. 
Third, for children who develop epilepsy, the parents playa crucial role in 
relation to rationalization and as suggested by Scal1lbler, the opinions of young 
children about their epilepsy may in fact be very similar to their parents' opin-
ions <H. This raises the question: Is it worthwhile developing a childhood self-re-
port scale if the same information can be collected more easily by questioning 
the parents? 
In most studies on disease severity in children, information comes from the 
parents, even when the aim is to assess the children's QoL 9}. Apparently, many 
researchers believe that the parents are so close to their child that their per-
ception of disease severity approaches the child's perspective. furthermore, such 
an approach rightly recognizes parents as experts all their own children &1. Self-
repon scales in childhood epilepsy are usually aimed at adolescents. Ratings by 
adolescents and their parents may well disagree 1\1. 
\Nhen subjective assessmenL<; of disease severity arc used, one must consid-
er the possibility of biased assessments. For example, when parents or clinicians 
are asked to quantify the severity of specific aspects of a child's epilepsy, they 
may be biased by the overall disease severity and may have difficulties to focus 
on the specific issue addressed in a scale. Anxiety and coping difficulties may 
bias ratings by the parents in severe cases of epilepsy_ In some cases, clinicians 
may feel the parents have produced 'idiosyncratic' scores, which are totally out of 
line with the clinician's view. Health measurement scales are to be used to sup-
plement the standard clinical information and results should always be inter-
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preted in this context. Nevertheless, it is not always within the physician's 
competence to judge at what point ratings by the parents become exaggerated 
and such a conclusion should, therefore, be reached with caution. 
Specific characteristics of childhood epilepsy 
The need for a childhood epilepsy-specific scale is further emphasized by 
the following specific characteristics of childhood epilepsy. 
Childhood epilepsy is often more complex than adult epilepsy. Children 
with chronic epilepsy frequently have polyrnorphous seizure disorders. 
Many children with chronic epilepsy are mentally retarded or have other 
impairments 16.60. In polyhandicapped patients, it is more difficult to determine to 
what extent the epilepsy contributes to the overall impainnenl 38. 
The incidence and nature of adverse effects reponed in children are differ-
ent from those in adults 7'\ll2. A scale to assess the presence and severity of ad-
verse effects of AEDs in children should be adjusted to the specific char-
acteristics of adverse effects in this population. 
Daily life and responsibilities in children are clearly different from those of 
adults and, thus, the consequences of seizures are different 85. Hence, the extent 
to which epilepsy is a handicapping disorder or causes disabilities In differs in 
adults and children. 
3.6. IMPROVEMENT OF OUTCOME MEASURES FOR CHILDHOOD 
EPILEPSY: ON·GOING PROJECTS 
Most research into improvement of outcome assessment and QoL in child-
hood epilepsy is of very recent date and only preliminary reports are available. 
Studies addressing QoL are focused on psychosocial, rather than physical or clin-
ical factors. For this reason a discussion of projects addressing physical aspects 
of QoL in childhood epilepsy has to be brief. 
Baker et al. ll proposed a multidimensional model to assess QoL in child-
hood epilepsy, including measures of S5, severity of adverse effects, mood and 
behaviour, intellectual function and physical co-ordination. A questionnaire 
based on this model was used in a study of lamotrigine in children with severe 
epilepsy and learning difficulties (Baker, written communication). 
In 1993, the Dutch Study Group of Epilepsy in Childhood has embarked 
on a project to improve outcome assessment in childhood epilepsy. It was decid-
ed to focus on the physical domain of QoL, specifically on SS and severity of 
side-effects. Subjective parent-completed scales were developed. Furthermore, a 
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scale was developed to measure the severity of disabilities due to restrictions in 
activities of daily life. 
Austin et al. have compared the QoL of children with asthma and children 
with epilepsy, using more generic and predominantly psychosocial measures 11. 
Children with epilepsy had a more compromised QoL in the psychological, so-
cial and school domain, children with asthma in the physical domain. 
Furthermore, social activities and parental supervision of children with new-
onset epilepsy were studied 9. Reduced child activity was found to be related 
to SF. 
Hoare and Russel51 published a pilot validation study with a newly devel-
oped parental QoL questionnaire measuring the impact of illness on children 
with epilepsy and their families. No data to support the scale's reliability were 
given. Their scale reflects a generic approach, as it was intended to be valid for 
children with other disabilities as well. 
In conclusion, the perfect assessment of outcome in childhood epilepsy will 
perhaps never be achieved, but in our opinion a combination of well validated 
and reliable measures pertaining to specific physical and psychosocial aspects of 
QoL, with medical-professional outcome variables in epilepsy, would seem an 
important step forward. In the near future, such new measures of outcome will 
become available. However, the final proof of their usefulness must come from 
clinical trials. 
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Table 3.1 Comparison of variables included in two scales measuring seizure 
severity (55). 
Liverpool 55 5cale 
Perception subscale 
Timing 
Aura 
Predictability 
Prevention 
Clustering 
Control 
Day-to-dayactivity 
Occurrence in sleep 
Ictal alld postictal slIbscale 
Overall severity of seizures 
Loss of consciousness 
Duration of loss of consciousness 
Lip smacking/fidgeting 
Postictal confusion 
Duration of postictal confusion 
Falling 
Headache 
Incontinence 
Tongue-biting 
Chalfont 55 5cale 
Warning before loss of awareness 
Nocturnal seizures only: divide score by 2 
Loss of awareness 
Duration of seizure 
Automatisms 
Time to return to normal from onset 
Fall to ground 
Incontinence 
Injury, including tongue-biting 
Drop, spill a held object 
Convulsion Cclonicjerking of limbs) 
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4.0 ABSTRACT 
Y-le have developed two outcome measures for childhood epilepsy: a 
seizure severity (55) scale and a side-effects (SE) scale. Both scales have been de-
signed for completion by parents. The scales were tested in two pilot phases and 
the results of this stepwise analysis are described here. The final scales' psycho-
metric properties were assessed in a group of 80 children with active epilepsy, 
representative of the population at whom the scales were aimed: children \vith 
chronic epilepsy, aged 4-16 years, including all seizure types and epilepsies, as 
well as children with neurological comorbidity. 
Both scales showed good internal consistency and test-retest stability. 
Although there was a significant positive correlation between the scales, this was 
low, indicating that the scales measure a different clinical trait. The SE scale con-
sisted of two subscales: a Toxic subscale, measuring the severity of dose-related 
side-effects, and a Chronic subscale, measuring the severity oflong-tenn behav-
ioural and cognitive side-effects. These suhscales for side-effects showed a high 
correlation, and can be used as a joint scale. The SS and SE scales have the po-
tential to improve outcome assessment in childhood epilepsy, and they can be 
used to assess important aspects of quality of life in this population. 
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4.1 INTRODUCTION 
4.2 
4.2.1. 
During the past decade, several tools have been developed to improve the 
assessment of treatment outcome in epilepsy. These efforts have focused on epi-
lepsy in adults. The high prevalence of epilepsy in children" and the fact that 
about 30% does not achieve total seizure controI 19.w, suggest that the devel-
opment of similar measures of outcome for a childhood epilepsy population is 
indicated. Such measures can prove useful in research and clinical practice. 
The purpose of treating epilepsy is to improve the child's life. It is impor-
tant to assess the effects of treatment on an individual basis. In the words of 
Freeman: "We need to treat seizures when, for that individual, the risk of having 
seizures and the consequences of having more seizures are worse than the risks 
and consequences of the treatment itself' 45. For clinicians concerned with 
epilepsy, the most important variables are frequency and severity of seizures, and 
prevalence and severity of side-effects of antiepileptic drugs (AEDs). How can a 
clinician determine whether an acceptable balance is achieved between seizure 
suppression and toxicity? In childhood epilepsy, a reliable and valid inventory of 
the child's health-related quality of life (QoL) %, would probably provide useful 
answers 33.H. 
QoL is generally seen as a multidimensional concept. In most studies ad-
dressing QoL in epilepsy, physical symptoms are neglected compared to psy-
chosocial issues :H. Measures of seizure severity and severity of side-effects are 
important aspects of the physical domain of QoL in epilepsy 12. The methodologi-
cal difficulties of self-report QoL assessments in a population of children with 
epilepsy (see previous chapter) suggest that the use of parent-report instead of 
self-report scales is justified. The majority of children with chronic epilepsy lacks 
the skills required for reliable self-report, because they are mentally retarded 6,) or 
simply too young. 
We describe two newly developed scales for parents of children with 
epilepsy: The Hague Seizure Severity scale (HASS) and The Hague Side-Effects 
scale (HASES). These scales were designed to measure the parents' perception of 
these two basic aspects of severity of epilepsy in children. 
METHODS 
Subjects 
Children were recruited from the outpatient populations of the depart-
ments of child neurology of two hospitals in The Hague (one children's hospital 
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and one general hospital) and the University Hospitals of Rotterdam, Leiden and 
Utrecht, four cities in the most densely populated area of the Netherlands. 
Parents were asked to participate by their child's own doctor and, after giving in-
formed consent, they were asked to complete a mailed questionnaire, including 
both scales, at home. All questions referred to the child's condition during the 
previous three months. All parents completed the HASS. The HASES was com-
pleted only by parents of children who were treated with AEDs. 
The treating physicians -experienced child neurologists- classified the 
seizures and epilepsies according to the current ILAE Classifications 28.29. 
4.2.2.1. Inclusion criteria 
4.2.2. 
Children aged 4-16 years, with a diagnosis of epilepsy and having experi-
enced at least one seizure in the past three months were included, regardless of 
seizure type or syndrome diagnosis. The physicians were asked to select parents 
with sufficient Dutch-reading skills to complete a questionnaire, thus, excluding 
most immigrant parents. 
Content 
'rYe developed scales to measure the parents' perception of the severily of 
seizures (HASS) and of side-effects of AEDs (HASES) in children with epilepsy. 
A 19-item pilot HASS was based on the Liverpool Seizure Severity scale -a valid 
and reliable self-report scale for adults 15_ to which new items were added as sug-
gested by the child neurologists who participated in the study. The definitive 13-
item HASS is presented in Appendix A. Questions 2, 3, and 7-13 have been 
translated from the Liverpool SS scale and subsequently modified to allow COlll-
pletion by the parents. The Liverpool scale includes some items with precise 
rather than subjective responses. We felt it was more consistent to include only 
items with subjective answer categories. 
The pilot HASES was based on items suggested by the child neurologists. It 
also included an open question inviting the parents to suggest alternative or 
additional items which they considered important within the scope of the scale. 
Ten sets of parents of children with uncontrolled epilepsy were asked to 
comment on the items and content of the pilot scales. Some questions were sub-
sequently added or rephrased. To some items in the HASS and all items in the 
HASES, a response category "unknO\vn" was added, to allow completion in case 
of a permanent impairment (like mental retardation or cerebral palsy). \\'hen a 
child is always incontinent or unable to express certain complaints, it seems 
impossible for the parents to answer a question about such problems occurring 
during or after a seizure, or because of AED treatment. The most severe score 
possible on both scales for children with (severe) permanent impairments was 
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consequently lower than for children without those impairments. 
Next, the scales were tested in two phases: (I) a pilot study in 25 patients, 
after which a preliminary psychometric evaluation was done; (2) a subsequent 
study in a larger population of 80 children and their parents, followed by a more 
extensive data analysis. We have chosen not to construct these scales on the 
basis of factor analysis, but first of all to construct the most homogeneous scales 
possible as suggested by Nunally ". 
4.2.3. Psychometric and statistical analyses (SS and SE Scales) 
4.2.3.1. Item analysis 
Two steps of item analysis were performed. (1) Corrected item-total corre-
lations (CITes) -the correlation between the item and the rest of tlle scale- were 
calculated, and items with a CITC < 0,20 were deleted. (2) Frequency dis-
tributions of answers were computed, and items where one alternative was cho-
sen in > 95% of cases were left out. 
4.2.3.2. Reliability analysis 
Crohnbach's alpha was computed as a measure of internal consistency of 
the final scales. A scale has sufficient internal consistency for research purposes, 
when alpha is at least 0.8 103. 
Test-retest reliability: of 22 consecutive parents who were asked to com-
plete a second questionnaire 14 days after the first, 18 parents responded. Pear-
son's R was used as a measure of test-retest stability. 
4.2.3.3. Distribution of the scores 
Items consisted of 4 or 5 point adjectival questions. A simple scoring sys-
tem was adopted with ratings ranging from 1 (most favourable) to 4 or 5 (most 
unfavourable) points for each item. 
Scale mean scores, SD values and frequency distributions of scores were 
established as these measures indicate the scales' potential to measure change. 
4.2.3.4. Correlations between scales and correlations with seizure frequency 
Spearman's rank correlation coefficient (Rs) was used as a measure of the 
relationships between the scales and of each scale with seizure frequency. \Ne 
used an estimation of seizure frequency in the preceding three months by the 
parents. 
--- 44 ---
SCALES FOR MEASURING SEIZURE SEVERITY AND SEVERITY OF SIDE-EFFECTS 
4.3 RESULTS 
In the final study. 81 children and their parents were included. The parents 
of one child did not return the questionnaire. The analysis of the HA55 was, 
thus, based on 80 completed questionnaires. The parents of 75 children com-
pleted the HA5E5, as 5 children were not treated with AEDs. The overall avail-
ability of data was excellent. None of the parents had any serious problems com-
pleting the scales. 
Demographic and clinical characteristics of the child~en included in the 
study are shown in Table 4.1. The majority of the children can be considered to 
be patients with intractable epilepsy. In 75% of the children, seizures were not 
under control after at least one year of therapy. Many children had symptomatic 
epilepsies and seizure types which are difficult to control. Mild to severe mental 
retardation was present in 37 (46%) children. The distribution of the number of 
AEDs/child reflected current clinical practice as monotherapy dominated and 
some children were not treated with an AED despite recurrent seizures. 
However, as one might expect in this sample, 40% of the children were treated 
with poly therapy. 
4.3.1. HA55 
4.3.1.1. Analysis after the pilot study 
One item concerning active seizure control by the child was left out. All 25 
parents answered negatively. No other changes were found necessary after the 
analysis of the pilot results. 
4.3.1.2. Final HA55 
After the item-analysis, we further reduced the number of items in the 
HA55. Items deleted because of a low CITC related to the following symptoms. 
Interruption of activities by the seizure, disability to speak during the seizure and 
seizure-related faecal incontinence. For several items relating to the same symp-
toms, we made a choice based on the best CITe. The final HA55 comprised 13 
items (Appendix A). 
The items represent the following areas of contenL Consciousness (4 questi-
ons), motor symptoms (2), incontinence (1), injuries/pain (3) and overall 55 (3). 
Ictal symptoms are addressed in 9 and predominantly postictal symptoms in 4 ques-
tions. The CITC values are listed in Appendix A. CITC values ranged from 0.22 to 
0_70. The highest CITC, indicating the item most representative of what the scale 
measures, was found for Q3 (How severe have the seizures been overall?). 
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Table 4.2 presents the results of reliability analysis, which indicate good in-
ternal consistency (Crohnbach's alpha 0.85) and a high test-retest correlation of 
0.93. Some scores were obtained on the lower extreme of the scale, which im-
plied that for these children the scale could not measure any improvement. No 
scores were produced in the upper extreme range of the scale. The mean score 
was> 2 SD values higher than the lowest possible score and 3 SD values lower 
than the highest possible score. 
4.3.2. HASES 
4.3.2.1. AnalysiS of the pilot study 
The pilot HASES was revised completely because of ambiguity of certain 
items and insufficient internal conSistency. We frequently found an inconsisten-
cy in the parents' response to a question concerning the presence of side-effects 
(12/24 parents reported 'no side-effects') and the subsequent responses on a list 
of items representing the most common side-effects (10 of these 12 parents re-
sponded positively to at least 1 item). Many parents added items to the pilot list 
of side-effects. Some of these items were included in a new 29-itern pool. 
4.3.2.2. Final HASES 
After testing the new pool of 29 items, three items were deleted: one with 
100% negative response (concerning vomiting), two with a low CITC (concern-
ing sleeplessness and increase of appetite/obesity). Subsequently, three subscales 
were formed, based on a clinical classification of the side-effects. The subscales 
were called 'Toxic' (14 items relating to dose-dependent gastro-intestinal and 
neurotoxic side-effects), 'Idiosyncratic' (6 items relating to gum hyperplasia, 
rash, hirsutism, hair loss, acne/pimples, itching), and 'Chronic' (6 items relating 
to cognitive and behavioural side-effects). 'vVe felt it was appropriate to analyze 
the internal consistency of these subscales first, before defining the final HASES. 
Internal consistency analysis of the subscales (n= 75) resulted in the follo-
wing alpha scores: Toxic 0.87; Idiosyncratic 0.47; Chronic 0.81. Alpha of the 
Idiosyncratic subscale was below the limit of 0.8, this subscale was consequently 
not included in the subsequent analysis. 
Test-retest stabilit), of the BASES was good (Table 4.2). On the HASES 
many children produced a score in the lowest possible range and the mean score 
was < 1 SD from the scale's lowest value. Very few children obtained scores in 
the high range of the HASES. 
The definitive HASES is presented in Appendix B, including a list of CITC 
values. The CITC values ranged from 0.24 to 0.77. The item with the highest 
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CITC in the Toxic subscale was "Fatigue" (0.77) and in the Chronic subseale 
"Decreased concentration" (0.64). 
Correlations 
Correlations between the BASES, its Toxic and Chronic subseales and the 
HASS are shown in Table 4.3. These indicate that the BASS and the BASES mea-
sured a different trait, as we found a low correlation between them. The Toxic 
and Chronic subscales largely measured the same clinical trait. 
There was a significant correlation between seizure frequency and the score 
on the BASS: Rs was -0.33 (P=0.004), meaning that frequent seizures were less 
severe. The correlation between seizure frequency and the score on the HASES 
was not significant: Rs was 0.18 (P=0.12). 
DISCUSSION 
HA55 
The 13~item BASS was easy to administer and reliable in terms of internal 
consistency and retest stability. The distribution of scores obtained in this sam-
ple suggested the scale has adequate potential to measure both positive and nega-
tive change in seizure severity. Its validity cannot be demonstrated using an ex-
ternal gold standard. However, face and content validity were appropriately es-
tablished. Furthermore, the question with the highest CITC dearly addressed S5, 
supporting the idea that the scale measured what it was intended to measure. 
The negative correlation between seizure frequency and the score on the HASS is 
in accordance with clinical intuition and suggests that parents were able to sepa-
rate seizure frequency and severity. Further evidence of construct validity must 
be obtained from subsequent clinical studies. 
It is well-recognized that assessment of SS adds to the overall reliability, 
sensitivity and clinical relevance of research on treatment outcome in uncon-
trolled epilepsy n.l<1.17.1l11.117. In addition to a measure of seizure frequency, the 
HASS can provide a more complete seizure-based outcome system for studies in 
uncontrolled childhood epilepsy. It is likely that, for children with recurrent 
seizures, it provides useful information pertaining to their QoL. 
HA5E5 
The HASES and its subscales have adequate internal consistency and retest 
stability. Mean scores were very close to the best possible scores. This indicates 
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that prevalence and severity of side-effects in the majority of the study popula-
tion were limited. This easily administered scale seems a useful and valid screen-
ing tool for identifying children with gastro-intestinal and neurotoxic side-ef-
fects. It is important to emphasize that the HASES was tested in an unselected 
sample of patients who have been treated for a long time. Tolerance to dose-
dependent side-effects may have reduced the scores on side-effects as addressed 
in the Toxic subscale --11.'>9. Probably, if children had been selected shortly after 
starting new medication, higher scores for dose-dependent side-effects might 
have resulted. 
The Idiosyncratic subscale failed the standard of internal consistency. This 
means that the symptoms and signs grouped in this subscale do not represent a 
homogeneous construct. The summation of scores over a number of items is ap-
propriate only if all items are measuring the same trait 1(\3. Although the validity 
of this subscale seems strong, we can not confidently conclude that a summation 
of scores on the items addressing idiosyncratic side-effects is appropriate. They 
may be useful as single items addressing idiosyncratic side-effects. One might 
argue that the Idiosyncratic subscale's low internal consistency is even support-
ive of the validity of the individual items. 
The considerable correlation between the Toxic and Chronic subscales 
makes it appropriate to use one HASES including the items of both subscales, in-
stead of separate subscales. 'rVe found no significant correlation between seizure 
frequency and the score on the HASES. This suggests that parents are able to 
separate seizures from side-effects. However, the complex relations between seiz-
ures and side-effects clearly warrant further studies. 
A quantification of subjective adverse effects is of importance in epilepsy 
treatment. Using a scale listing the most frequent side-effects may be a particu-
larly infonnative approach. In our pilot study, the majority of parents, reporting 
"no side-effects" to a global question, did report complaints on a subsequently 
presented list of side-effects. As such, the BASES may contribute to a better 
screening for the presence of side-effects, as well as to the assessment of their 
severity. 
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Table 4.1 Demographic and clinical variables of the sample 
Number of children 
Mean age (SO) 
Sex 
Mean duration of epilepsy (SO) 
Epilepsy classification 
Seizure classification* 
Number of AEOs per patient 
80 
9.6 years (3.4) 
34 (43%) girls 
4.7 years (4.0) 
local ization· related 
- idiopathic with age-
related onset: 12 (15%) 
. s)~nptOlnatic: 31 (39%) 
generalized 
- idiopathic with age-
related onset: 11 (14%) 
- generalized idiopathic or 
symptomatic: 18 (23%) 
"nclassified: 8 (10%) 
simple partial: 18 
complex partial: 24 
secondary generalized: IS 
absences: 14 
myoclonic: 3 
clonic: 1 
tonic: 3 
tonic-clonic: 9 
atonic: 7 
no AEO: 5 (6%) 
1 AED: 43 (54%) 
2 AEDs: 21 (26%) 
3 AEOs: 10 (13%) 
4 AEOs: 1 (1%) 
* In the preceding 3 months; 13 children had more than 1 seizure lype. 
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Table 4.2 Results of reliability analysis of the scales for seizure severity (HASS) and 
side-effects (HASES) and its subscales for toxic side-effects and chronic 
side-effects. 
Scale Alpha Retest 
HASS (13 items) 0.85 0.93 
HASES (20 items) 0.88 0.91 
HASES subseales: 
Toxic (14 items) 0.87 
Chronic (6 items) 0.81 
Alpha: Crohnbach's alpha (internal consistency)_ Retest: Pearson R between first 
test score and retest score after 14 days. 
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Table 4.3 'Correlations between scores on the scales for seizure severity (HASS), 
side-effects (HASES) and subscales for toxic side-effects and chronic 
side-effects (Spearman rank correlation). 
HASS 
toxic subscale 
n= 75 
HASES 
0.25 
1'=0.027 
toxic subscale 
0.20 
1'=0.080 
--Sl--
chronic sUbscale 
0.23 
1'=0.048 
0.58 
1'<0.001 
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Appendix A: THE HAGUE SEIZURE SEVERITY SCALE and CITC values in 80 children. 
Questions relate to your child's seizures in the past 3 months. 
Ql. How often do you notice a decrease of consciousness 
during a seizure in your child? 
a. always 
b. usually 
c. sometimes 
d. never 
Q2. How long does such a decrease of consciousness last? 
(From time of onset to time of normal consciousness) 
a. very long 
h. long 
c. short 
d. ver), short 
Q3. How severe have the seizures been overall? 
a. very severe 
b. severe 
c. mild 
d. very mild 
Q4. Are there any muscle jerks or cramps in the arms or legs 
during an attack? 
a, always 
b. usually 
c. sometimes 
d, never 
Q5. How long do the jerks or cramps last during an attack? 
a. very long 
b. long 
c. shon 
d. very short 
e. does not apply, there are no jerks or cramps 
Q6. How noticeable are the seizure symptoms? 
a. very noticeable, everyone will notice an attack 
b. fairly noticeable, most people will notice an 
attack 
c. not :'o'ery noticeable, most people will not no lice 
d. not at all noticeable, you have to be ver)' alert 
to notice an attack 
(CITC " 0.33) 
(CITC " 0.59) 
(CITC " 0.70) 
(CITC" 0.48) 
(CITC" 0.54) 
(CITC" 0.64) 
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Q7. During or aher an atlack, how often does your child seem Confused? 
a. always 
h. usually 
c. sometimes 
d. never 
Q8. During an attack, how often does your child wet him/herself? 
a. always 
b. usually 
c. sometimes 
d. never or unknown, my child is permanently incontinent 
(CITC ~0.49) 
(CITC ~ 0.41) 
Q9. During an attack, how often does your child bite his/her tongue? (CITe 0.49) 
a. always 
b. usually 
c. sometimes 
d. never 
QlO. How often does your child become injured during an attack 
Cather than biting the tongue)? (CITC ~ 0.22) 
a. always 
b. usually 
c. sometimes 
d. never 
Qll. After the attack has finished, is your child sleepy? (Including sleepiness 
caused by the use of rescue medication like Diazepam) (CITC '" 0.67) 
a. always 
b. usually 
c. sometimes 
d. never 
Q12. After an attack, does )'our child complain of sickness, 
headache and/or pain in the muscles? 
a. always 
b. usually 
c. sometimes 
d. never or unknown, my child would not be able to complain 
about that 
Q13. After an attack, how long does it take, until your child can resume 
(CITC ~ 0.43) 
normal activity? (CITC = 0.65) 
<l. very long 
b. long 
c. short 
d. very short or direct after an attack 
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Appendix B: THE HAGUE SIDE-EFFECTS SCALE and CITC values in 75 children. 
The following questions concern possible side-effects of the medication for 
epilepsy. To explain: If your child has trouble walking, and you believe that this 
is caused by the medication, this is called a side-effect. If this difficulty with 
walking has another (probable) cause, ego a handicap or a broken leg, this does 
not count as a side-effect. 
Have you noticed any of the following side-effects of 
anti epileptic medication in your child during the past three 
months? 
a::: yes, it is a very serious problem 
b= yes, it is a moderately serious problem 
c= yes, it is a mild problem 
d= no or not applicable or cannot be assessed because of impairment 
I drowsiness, sleepiness a. b. C. d. 
2 dizziness a. b. C. d. 
3 uncertainty when walking a. b. C. d. 
4 falling a. b. C. d. 
5 sickness a. b. C. d. 
6 difficulty with defecation a. b. c. d. 
7 diarrhoea a. b. C. d. 
8 shaking, trembling a. b. C. d. 
9 speech difficulties a. b. C. d. 
10 double or blurred vision a. b. C. d. 
II headache a. b. C. d. 
12 fatigue a. b. C. d. 
I3 loss of appetite a. b. C. d. 
14 depression a. b. C. d. 
15 hyperactivity a. b. C. d. 
16 temper tantrums, aggression a. b. C. d. 
17 slowness a. b. C. d. 
18 poorer school results a. b. C. d. 
19 decreased concentration a. b. C. d. 
20 behavioural disturbance a. b. C. d. 
Note: CITCs relate to the full HASES, which addresses toxic sick-effects 
(items 1-14), alld chmllic side-effects (items 15-20). 
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0.62 
0.48 
0.66 
0.56 
0.43 
0.31 
0.24 
0.45 
0.41 
0.49 
0.55 
0.77 
0.40 
0.54 
0.31 
0.32 
0.61 
0.63 
0.64 
0.57 
5 SEIZURE SEVERITY IN CHILDREN WITH EPILEPSY: 
A PARENT-COMPLETED SCALE COMPARED WITH 
CLINICAL DATA. 
].A. Carpa),,]. Vermeulen, H. Stroink, O.F. Brouwer, A.CB. Peters, 
A.P. Aldenkamp, CA. van Donselaar, and W.F.M. Arts. 
Epilcl'5ia 1997;38:346-352. 
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5.0 SUMMARY 
Purpose- We wished to compare a parent-completed scale quantifying seizure 
severity (55) in children with various seizure types with the clinicians' impres-
sion of 5S and other clinical data. 
Methods- The parents of 117 children with recurrent seizures completed a 13-
item, subjective scale (The Hague Seizure Severity Scale, HASS). Eight treating 
neurologists quantified SS on a lO-point Visual Analog Scale (VAS) and supplied 
other clinical data. 
Resu/ts- Both the HASS and the VAS assessments of SS showed considerable vari-
ation within one seizure type. 5ignificant differences were found between groups 
with 1) absences and simple partial seizures, 2) complex partial seizures, and 3) 
generalized tonic-clonic seizures. The correlation coefficient between the 
neurologists' and the parents' scores was 0.45 but did not exceed 0.26 after strati-
fication for seizure type. The parents' score was not substantially influenced by 
various other clinical variables. The neurologists' score was correlated with resis-
tance to treatment and presence of mental retardation. 
Conclusions- The 5S ratings of the parents and the neurologists were not substan-
tially correlated. The consideration that parents, as eye-witnesses to the seizures, 
are probably better judges of 5S than clinicians may favour the use of a parent-
completed scale to quantify SS. The HASS is a valid and reliable measure of par-
ent-perceived SS that can be useful as an outcome measure in childhood 
epilepsy. 
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5.1 INTRODUCTION 
Seizures in epilepsy are of variable severity. Because one quarter to one 
third of children with new onset epilepsy will not become seizure free in a short 
time, Ill.easures of seizure severity (55) may contribute to a more complete 
assessment of the otltcome after treatment 27. A 55 scale should measure the COlll-
ponents of seizures that concern patients and their carers 3I and has its place in 
assessments of quality oflife (QoL) in epilepsy n. Since the 1980s, several speci-
fic scales to measure 55 have been developed, incltlding self-report 15 and physi-
cian-based scales 32.8+. As scales developed for adults, they are not appropriate for 
children H. The development of self-report scales for children raises a number of 
specific methodological problems 35m, e.g., children's lack of understanding of 
disease M. The use of a parent-based instrument in childhood epilepsy allows the 
inclusion of children who obviously lack the ability to participate in self-report 
assessments, such as mentally retarded or very young children. Furthermore, am-
nesia for seizures could make results using self-report scales less useful. Alter-
natively, a physician-based scale may be used to assess seizure severity. 
We performed a study using a parent-completed scale specifically devel-
oped for use in childhood epilepsy: the Bague Seizure Severity scale (BASS 
scale) 26. We compared results with a standardized assessment of the neurolo-
gists' global impression of seizure severity, using a Visual Analogue Scale (VAS) 
(for a brief introduction of this technique see, e.g., 5treiner and Nonnan 1\.'3). Our 
intention was to explore the relationship between seizure severity scores as as-
signed by parents and neurologists and seizure type. Because clinicians and pa-
tients perceive differences in global seizure severity for specific seizure types 
15.31,84, we used this analysis as a method of validation of the parents' and neurolo-
gists' assessments. We also wished to determine if the variability in reported 
seizure severity per seizure type would justify the effort of a specific measure-
ment of seizure severity. Furthermore, we intended to provide a systematic com-
parison between the parents' and the neurologists' assessments of seizure severity 
and various clinical data. 
5.2 MATERIALS AND METHODS 
5.2.1 Parental HASS scale 
The BASS scale is shoml in Table 5.1; the full scale and its development 
were published previously 1~. The HA55 scale quantifies the parents' opinion on 
the severity of 13 possible ictal and postictal problems in the previous three 
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months. It was based partly on items derived from the Liverpool SS scale 1\ with 
subsequent modifications to allow for completion by the parents, and on items 
suggested by parents and neurologists in a pilot study. From a pool of pilot 
items, the most appropriate items were selected based on item-analysis, (aimed at 
constnlcting a homogeneous scale) and content validity analysis. An assessment 
of reliability indicated good internal consistency (Crohnbach's alpha 0.85) and 
retest stability (r=0.93) of the HASS scale ". 
VAS and clinical data 
The treating neurologist classified the seizures according to the 1981 ILAE 
Classification 23. Because children were treated in an outpatient setting, the neu-
rologists based their judgements on a description of the seizures by the parents 
or other eyewitnesses. Furthermore, the neurologists were asked to rate 'global 
seizure severity' on a lO-point VAS, with 1 representing the least severe seizure 
imaginable and 10 representing the most severe seizure. Previous discussions in 
our group had shown that there was good agreement about the clinical factors 
that were related to seizure severity. The neurologists had no knowledge of the 
parents' score on the HASS scale. The medical records of all children were re-
viewed for information about the following variables: age, sex, duration of epi-
lepsy, current treatment with antiepileptic drugs (AEDs), and schooling level. 
Setting and subjects 
Children and their parents were recruited from the outpatient populations 
of the child neurology departments of three university hospitals, one paediatric 
hospital, and one general hospitaL Eight paediatric neurologists participated in 
the study. The study protocol was approved by the ethics committees of the par-
ticipating centres. 
Children aged 4-16 years with a diagnosis of epilepsy and at least one seiz-
ure in the previous three months were included. The neurologists selected par-
ents with sufficient written Dutch language skills to be able to complete a ques-
tionnaire. The parents were asked by their regular specialist to participate and re-
ceived written information about the study. They were requested to complete the 
questions on the BASS scale at home. Parents were also asked how many differ-
ent types of seizures they had observed in the previous three months, to estimate 
the seizure frequency, and to describe the differences between seizures in case of 
multiple seizure types. Trrespective of the number of reported seizure types, par-
ents were not asked to complete separate questionnaires for different seizure 
types. 
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Construct validity 
Clinicians and patients perceive similar global differences in severity be-
tween seizures types 15.3I M. For example, generalized tonic-clonic (GTe) seizures 
are considered to be at the severe end of the spectrum. We studied the ability of 
both the HASS scale and the neurologists' VAS-assessments to detect these differ-
ences, which would support their validity. 'ATe created three subgroups: (in order 
ofincreasing seizure severity) Minor, Intermediate and Major. The Minor sub-
group consisted of children with absences and simple partial seizures, the Inter-
mediate subgroup of complex partial seizures and the Major subgroup of GTe 
seizures. To avoid mixed responses, we included only children who had one sin-
gle seizure type. Children with more than onc seizure type, e.g., those with a 
combination of complex partial seizures and secondarily GTC seizures or of dif-
ferent generalized seizure types were not included. To decide if the child had one 
or more seizure types, we considered information obtained from both the neurol-
ogist and the parents. 
To provide additional data on the HASS scale's and VAS's relation with 
clinical data and discriminant validity -which means that these measures should 
not be correlated substantially with measures of different entities than seizure 
severity-, we determined whether the scores were independent of the child's age, 
sex, duration of epilepsy, seizure frequency, schooling level and mono- or poly-
therapy. We expected a negative correlation between seizure frequency and 
seizure severity in the total group, because seizure type and frequency are associ-
ated variables: Children with absences -seizures at the least severe end of the 
spectrum- have a much higher seizure frequency than children with other seiz-
ure types. After stratification for seizure type, however, the scores should not be 
substantially correlated with seizure frequency. We had no reason to expect sig-
nificant correlations between scores reflecting seizure severity and the remaining 
demographic or clinical variables of the children. 
Statistical methods 
Correlations were computed with Pearson's r-value. To analyze group 
differences we used Student's t-test or analysis of variance CANOVA) with post 
hoc Scheffe test. A significance level of p < 0.05 was chosen. The distribution of 
scores in the seizure type subgroups was plotted and compared with the distribu-
tion of scores in the total group, and a plot was constructed showing the rela-
tionship between the parents' and neurologists' scores. 
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5.3 RESULTS 
One hundred and twenty children were selected for the study. and 117 
(97.5 %) questionnaires were returned. The HASS scale was completed by the 
mother in 58, the father in 8, both parents in 49, and other caregivers in 2 cases. 
The overall availability of data was excellent, reflecting that parents had no seri-
ons problems in completing the questionnaire. Demographic and clinical charac-
teristics of the 117 children are shown in Table 5.2. Most of the children includ-
ed had had recurrent seizures for> one year despite treatment. Of the 117 chil-
dren, 99 children had had one single seizure type, and ]8 had had more than 
one seizure t)1Je in the previous three-month period. Of the children with more 
than one seizure type nine had an encephalopathic epilepsy with a combination 
of generalized seizures (Lennox Gastaut syndrome) and nine a combination of 
partial or secondary generalized seizure types. 
5.3.1 Validity 
5.3.2 
The three subgroups of children with only one seizure type (n"92) based 
on their assumed difference in seizure severity were the following: 1. Minor sub-
g,rQ!l}2: 33 children with either simple partial seizures, all experiencing motor 
symptoms or absences and in our opinion representing a category of least severe 
seizures; 2. Intermediate subgroup: 30 children with complex partial seizures; 
and 3. Major subgroup: 29 children \vith secondary generalized or primary GTC, 
representing the highest level of seizure severity. 
The differences in mean VAS scores were significant between the Minor, 
Intermediate and Major subgroups (ANOVA, D.F. 2, F ratio 18.6, P< 0.000] for 
overall difference, with the Scheffe test showing a significant difference between 
all three subgroups). Mean BASS scale scores in these three subgroups were also 
significantly different (ANOVA, D.F. 2, F ratio 34.4, P< 0.000] for overall differ-
ence, Scheffe test showing a significant difference between all three subgroups). 
Seizure severity and seizure type 
A plot of HASS scale score and VAS score frequencies in all children is 
shown in Fig. S.lA and S.lB. Both plots show that only a few patients had ex-
tremely low or high scores; most scores were distributed around the middle of 
the scale ranges. Fig. S.lC and 5.lD show the scores for different seizure t)l)es 
(in the children with one seizure tl1Je only) for the parental HASS scale and the 
neurologists' VAS assessments, respectively. 
Fig. 5.1 C and S.lD demonstrate a considerable variability in seizure severity 
scores within one seizure type and considerable overlap in scores between 
seizure types. 
--- 61 ---
I 
~ 
~ 
I 
HASS - parents' scores 
3 .... nurnberofpatients 
0 
2 
2 
5 
0 
5 :.::.. 
O~ -, 
5 
o t:J 
11 
25 
20 
15 17 
-
9 
r- 4 
tel 0 
13-1617-2021-2425-2829-3233-3637-4041-4445-4849-52 
lOa]] 117 chlldren I 
5.1 A 
8 
6 
4 
2 
o 
HASS - parents' scores by seizure type 
nurnberoipatients 
PI [ r • 
,ril ~ U- • I ~ I r F FI 
13-1617-2021-2425-2829-3233-3637-4041-4445-4849-52 
IOAbs OS? Se? _GTe! 
5.1 C 
VAS - neurologists' scores 
3 ) 
2 , 04 
-
2 ) 20 
-'-
, 
12 
..J."---14 
)--
.~ f1-n..2-. rI 5 o 
2 3 4 5 6 7 8 9 10 
Icalll1? childrenl 
5.1 B 
VAS - neurologists' scores by seizure type 
1- numberofpatients , 
8 
6 
4 
1m r- i~ I Pl ~ I I 2 o 
2 3 4 5 6 7 8 9 10 
IcaAbs oSP ae? _GTel 
5.1 D 
I~ 
N 
C ;:; 
I~ 
'" ~ -<
~ 
n 
~ 
n 
o 
" ;:; 
;:; 
o 
'" 
=; 
1= 
'::0 
Z 
" 
" o ~ 
5.3.3 
SEIZURE SEVERITY SCALE COMPARED WITH CLINICAL DATA 
FIG. 5.1. Frequency distribution of seizure severity scorcs assigned by tile parcnts 
usillg the Hague Seizure Severity Scale (HASS scale) (rallge: 13 (least sevae) to 54 
(Illost severe)) "lid by the Ileumlogists usillg a Visual Allalogue S",le (VAS) (rallge 1 
(least severe) to 10 (IIIoSt severe)). (A) HASS scale scores ill all childrell. (B) VAS 
scores ill all childrell. (e) HASS scale scores ill JOllr grouI" with sillgle seizure types. 
(D) VAS seol·es ill Jour gmups with sillgle seizure types. Abs~absellces; SP~si",ple 
partial; ep~colllplcx partial; GTe~prilll"')' or secolld",), gellemlized tOllic clollic 
seizures. 
Mean parental scores on the I-lASS scale per seizure lype are shown in 
Table 5.3. The simple partial seizure group had obtained a higher mean score 
than the group with absence seizures, but the difference was not significant. The 
mean score in the complex partial seizure group was higher than the mean in the 
simple partial seizure group and lower than the mean for GTe seizures, the latter 
group showed little difference between primary and secondarily GTe seizures. 
Mean VAS scores assigned by the neurologists per seizure type are also 
shown in Table 5.3. The absence and simple partial seizures were assigned a 
comparable low mean VAS score (2.9 and 3.2, respectively, on a lO-point scale). 
The complex partial seizures obtained an intermediate VAS rating (mean 4.6). 
The highest VAS scores were assigned to children with GTe seizures, again with 
little difference between primary and secondarily GTe seizures (mean 5.7 for 
both). 
Comparison of parents' and neurologists' scores 
We noted a statistically significant correlation (r ~ 0.45, P < O.OOI) be-
tween the parental HASS scale score and the neurologists' VAS seizure severity 
rating (Fig. 5.2). After stratification for seizure type, the correlations between the 
parents' and neurologists' ratings were not significant and r values ranged from 
0.10 to 0.26 (see Table 5.3). 
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VAS by lIeurologists 
9 
00' 0' 
. ... . 0 
6 
.. ·0"0 
o --0-
00 • o· ... 
12 18 24 30 36 42 48 
HASS scale by pamIts 
FIG. 5.2. Relation between parents' scores on the Hague Seizure Severity Scale 
(HASS scale, x-axis) alld lIeurologists' scores oj SS all a lO-poillt Visual Allalogue 
Scale (VAS, y-axis) ill 117 clIildrell (Pearsall 1'=0.45). Olle case (solid circles), 
2 cases (dolled circles), 3 cases (small dolled ovals), 4 cases (large doued ovals). 
5.3.4 Parental scores on the HASS scale and clinical data 
\Ve noted a significant correlation (r = -0.28) between seiZUre frequency 
and HASS scale score in the total group, indicating that the most frequent 
seizures tended to be the least severe (see Table 5.4). This finding is largely ex-
plained by the inclusion of children with absences. Children with absence 
seizures had high seizure frequencies as compared with children with other 
seizure types (Table 5.3), and the absences were assigned the lowest HASS scale 
score (mean 20.9). We noted no correlation exceeding r=0.14 between HASS 
scale score and seizure frequency after stratifying for seizure type. There was a 
significant correlation between age and HASS scale score (r=0.19). Table 5.3 
shows that this could not be explained by differences in age between seizure 
types. Furthermore, the parents' HASS scale score did not correlate significantly 
with duration of epilepsy (see Table 5.4). Vh noted no significant difference in 
the mean BASS scale score between girls and boys, between children receiving 
special education (for mild to profoundly retarded children) and those attending 
normal schools, or between children receiving mono therapy and children receiv-
ing poly therapy. 
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Neurologists' scores on the VAS and clinical data 
The VAS score was not correlated with seizure frequency. The VAS score 
correlated significantly \\1th duration of epilepsy (r=0.28), but not with age 
(Table 5.4). Table 5.3 shows that this correlation was not explained by dif-
ferences in duration of epilepsy between seizure types. Differences in VAS score 
were Significant between children attending normal schools and those attending 
special schools (mean scores, 4.1 versus 5.7; P<O.OOl; t-test) and between chil-
dren receiving mono therapy and those receiving poly therapy (mean scores, 3.3 
versus 5.8; P<O.OOl; t-test). Differences between boys and girls were not signifi-
cant. 
5.4 DISCUSSION 
\Ve compared a parent-completed scale quantifying seizure severity in 
childhood epilepsy with clinical data, including a standardized seizure severity 
rating by the treating neurologist. The use of a seizure severity scale allows quan-
tification of the variability in severity of seizures beyond fixed ratings based on 
seizure type. This appears to be relevant because scores on the parental HAS5 
scale as well as on the neurologists' VAS showed considerable difference in seiz-
ure severity between children with identical seizure types. 
55 can not be measured objectively, and opinions are necessarily induded 
in its quantification, which raises the question of whose point of view ought to 
be be preferred in clinical trials and practice. Clinicians may prefer professional 
assessments of disease severity, clahiling a higher degree of objectivity or scien-
tific validity. However, because doctors rarely witness a child's seizures, the par-
ents are probably the best judges of 55 and the impact on their children. For this 
reason alone, it may be more appropriate to use a parent-completed rather than a 
physician-completed 55 scale. These considerations prompted us to develop the 
parent-completed scale used in the present study. Nevertheless, because a 55 
scale will be used in a clinical context, we believed that it was important to com-
pare parental ratings with a 'clinical global impression' by professionals and with 
other clinical data. 
\Ve used a VAS scale to quantify the clinicians' opinion of 55 because it 
has the merit of Simplicity 1\'3 and has been used in previous studies for an assess-
ment of 55 St.!!!. \Ne did 110t analyze the reliability of the VAS ratings, but the reli-
ability of a one-item scale is inevitably inferior to that of a multiple-item test 1l'3. 
Despite these differences in scales, we think that a meaningful comparison of 
scores can be made, because both scales quantified 55. 
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Overall, the neurologists' score predicted < 20 % of the variability of the 
parents' score in the total group, and we noted even lower correlations after 
stratifying for seizure type. Furthermore, the parental HASS scale made a dis-
tinction between absences and simple partial seizures -although the difference in 
mean scores did not reach statistical significance-, and the neurologists' score on 
the VAS did not. We conclude that there was a substantial difference between 55 
ratings assigned by the parents and the neurologists in the present study. Our 
data do not suggest that this difference can be explained by a lack of validity of 
the HASS scale or VAS. 
We noted significant differences in HASS scale and VAS scores between 
subgroups including, respectively, 1) absences and simple partial, 2) complex 
partial, and 3) generalized tonic-clonic seizures, that supported the validity of 
both measures. Furthennore, these data confirmed that parents correctly iden-
tified the appropriate seizure characteristics in their children. For the parental 
HASS scale, we noted no evidence of a substantial bias related to a variety of 
clinical variables, including seizure frequency after stratification for seizure type. 
Therefore, the parents were able to isolate 55 from a range of variables, all of 
which may contribute to the 'overall severity of epilepsy' H. In contrast to the 
parents' score, the neurologists' score was not correlated with seizure frequency 
in the total group, although we had hypothesized that the most frequent seizures 
would be the least severe. Resistance to AED treatment may have influenced the 
neurologists' score, as the mean score of children receiving poly therapy was 
higher than that of children receiving monotherapy. The VAS scores were also 
higher for children attending special schools for retarded children as compared 
\vith scores of children with normal intellectual abilities. 
We did not examine the psychosocial status of the parents. Psychosocial fac-
tors, such as depression or an.xiety, may have influenced the parental ratings in our 
study. We previously reported low to moderate (between 0.16 and 0.38) correlations 
between scales measuring parent-perceived 55, severity of side-effects and severity of 
restrictions due to epilepsy 2;. Had these scores reflected the parents' anxiety to a 
large extent, more substantial correlations probably would have resulLed. 
Clinical trials in epilepsy using a traditional design, with seizure frequency 
as the only outcome variable often cannot assess differences in efficacy between 
AEDs. Therefore, the inclusion of a measure of 55 may increase the sensitivity 
and relevancy to patients. Clinical trials that have included a measure of 55 are 
rare. The HASS scale was based on the Liverpool Seizure Severity scale 15, a reli-
able and valid self-report scale for adults pertaining to QoL in epilepsy It. Used in 
a clinical trial, the Liverpool Seizure Severity scale enhanced the sensitivity of 
outcome assessment ](1;. 
We are now evaluating scales in a comparable format addressing the sever-
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ity of adverse effects of AEDs and restrictions in activities of daily life of children 
with epilepsy. Our goal is to combine these scales to quantify the parents' opin-
ion on some of the most relevant disease-specific problems affecting QoL in chil-
dren with epilepsy. Many researchers 12.H.n have suggested that it is relevant to 
include scientific measures of the patients' opinion -often addressed as QoL mea-
sures- in clinical studies of patients with epilepsy. The HASS scale, however, re-
flects the parents' and not the child's opinion. The use of the parents as the 
source of information in the present study corresponds well to previous QoL re-
search in children '13. Because of their age-dependent understanding of disease 
and cognitive abilities, children represent a problematic group [or use of self-re-
port scales n.91. Children with mental retardation constitute another group that 
appears to be less accessible for use of self-report measures. 
We suggest that the HASS scale could be a usefullool for clinical trials in 
children with recurrent seizures. In daily practice, the HASS scale could be useful 
to guide decisions regarding when to start treatment and how to respond to 
recurrences despite treatment or after discontinuation of drugs. 
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Table 5.1 Items addressed in the Hague Seizure Severity scale 
1. frequency of impairment ofconsciousness* 
2. duration of impairment of consciousness 
3. overall seizure severity 
4. frequency of jerks or cramps 
5. duration of jerks or cramps 
6. noticeability of altered behaviour during seizure 
7. frequency of confusion during or after attack 
8. frequency of urinary incontinence during seizure 
9. frequency of tongue or cheek-biting 
10. frequency of other injury related to attack 
11. frequency of postictal sleepiness 
12. frequency of postictal nausea, headache or muscle pain 
13. time to normal function after attack 
*Frequencies represent the number of times a problem occurs as compared with 
the total number of seizures. All questions relate to the seizures in the previous 
three months. All items have 4 or 5 adjectival (subjective) response categories (e.g. 
always, usually, sometimes, never). Scoring for each item: 1 point for the most 
favourable answer, to 4 or 5 points for the most unfavourable answer. 
Total scale score ranges from 13 (lowest seizure severity) to 54 (highest seizure 
severity). 
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Table 5.2. Demographic and clinical variables of 117 children 
Mean age (SD) 
Sex 
Mean duration of epilepsy (SD) 
Epilepsy classification 
Two or more seizure types 
Number of AEDs per patient 
Mental retardation# 
9.7 (3.3) years 
67 (57%) boys 
4.2 (3.8) years 
local ization-related 
- idiopathic with age-related onset: 16 (14%) 
- symptomatic: 46 (39%) 
generalized 
- idiopathic with age-related onset: 23 (20%) 
- symptomatic: 24 (21%) 
unclassified 8 (7%) 
18 (15%) 
no AED: 8 (7%) 
1 AED: 67 (57%) 
2 AEDs: 31 (26%) 
3 AEDs: 10 (9%) 
4 AEDs: 1 (1%) 
45 (38%) 
# Mental retardation was based 011 scllooling level. 
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Table 5.3. Demographic and clinical variables, seizure severity and seizure type 
Absence SP 
Number 17 16 
Age mean 9.3 (2.9) 10.5 (3.I) 
Complex 
Partial 
30 
9.70.2) 
PGTC 
13 
9.9 0.5) 
SGTC 
16 
10.1 0.5) 
Duration of epilepsy 3.7 (4.0) 2.4 0.2) 4.5 (3.8) 2.8 (2.5) 4.8 (4.2) 
Seizure frequency 2049 (540) IS (29) 103 (252) 9 (12) 4 (6) 
Score VAS 3.2 (1.6) 2.9 (1.2) 4.6 (2.0) 5.7 (1.9) 5.7 (1.4) 
Score HASS scale 20.9 (4.2) 26.9 (7.5) 30.9 (6.9) 37.9 (6.6) 36.7 (4.5) 
VASIHASS scale r 0.25 (ns) 0.26 (ns) 0.25 (ns) 0.10 (ns) 0.10 (us) 
Only children with one single seizure type are included in this table. 
Data are mean values with standard deviations between parentheses. SP:oosimple 
partial seizures. P(S)GTC=primary (secondary) generalized tonic-clonic seizures. 
Seizure frequency=the mean number of seizures in the previous three months. 
VAS score=the neurologists' rating of seizure severity on a IO-point Visual 
Analogue Scale. Score HASS scale=the score on the Hague Seizure Severity Scale 
(scale ranges 13-54). VAS/SS Scale r=Pearson correlation between VAS score and 
HASS scale score; nS=llot significant. 
Analysis of variance (ANOVA) showed thaI differences in age and duralion of 
epilepsy were not significant between any two seizure types. Seizure frequency in 
the absence group was significantly different from that in all other groups. Other 
between-group differences in seizure frequency were not significant. 
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Table 5.4. Univariate analysis of correlation between clinical variables and parents' 
and neurologists' seizure severity score (Pearson r value) in 117 children 
Parameter Parents$ Neurologists+ 
Age 0.19 (p=0.037) * -0.11 (p=0.239) 
Duration of epilepsy 0.16 (p=0.094) 0.28 (p=0.003) * 
Seizure frequency# -0.28 (p<O.OOl) * -0.03 (p=0.746) 
$ Parents' score on the Hague Seizure Severity scale 
+ Neurologists' rating of seizure severity on a IO-point Visual Analogue Scale. 
* Significant at p<0.05 
# Seizure frequency=mean number of seizures in the previous three months. 
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6.0 ABSTRACT 
Objective· To quantify the prevalence and severity of subjective side-effects (SE) 
as perceived by parents of children taking anti epileptic drugs (AEDs), and their 
association with clinical risk factors for SE. 
Methods- We used a parent-completed lO-item scale (The Hague Side Effect 
Scale, HASES) in 115 children on AEDs aged 4-16 years. Results were compared 
with a control group of 25 children on medication for asthma. Furthermore, we 
studied the associations between parent-reported SE and clinical data, including 
number and dosage of AEDs, and the clinician's global evaluation of the severity 
of SE. 
Rcsillts- In 82% of the children at least one SE was reported. Median scores on 
the HASES were not significantly different between children on AEDs and chil-
dren on anti-asthma medication. There was no significant correlation between 
the parental HASES score and the clinicians' evaluation of the global severity of 
SE. There was no significant relationship between the HASES score and the 
dosage of AEDs, or the use of mono- or poly therapy. Neither age, sex, duration 
of epilepsy, presence of mental retardation, seizure activity or presence of a 
steady state AED regimen for 90 days were substantially associated with the 
HASES score. 
COlldliSioll- In this sample, the prevalence of subjective SE was high. There was a 
lack of association between prevalence and severity of subjective SE as reported 
by the parents, and number or dosage of AEDs. However, in this observational 
study this may reflect adjustment of medication to the individual child's ability 
to tolerate AEDs. It remains questionable if the subjective SE as reported by the 
parents were causally related to the AEDs, at least they were not specific for chil-
dren taking AEDs. 
Keywords: antiepileptic drugs, side-effects, epilepsy, quality of life. 
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6.1 INTRODUCTION 
Most children with epilepsy are treated with antiepileptic drugs (AEDs). AEDs 
are often associated with minor, subjective side-effects (SE).2.M Few studies pro-
vide details about prevalence and severity of such SE. Furthermore, most meth-
ods sections in publications about treatment with AEDs are rather vague about 
the assessments of SE.67 Because subjective SE may influence clinical decisions 
and may undermine compliance, a valid and reliable tool for their quantification 
would seem usefuL If patients are children with epilepsy, the ideal of self-report 
scales reflecting the patient's opinion about SE is often unrealistic. Especially, for 
young or mentally retarded children the parents lIlay be the most reliable source 
of information.3~.93 
\Ve have previously described a method for a standardized quantification of 
the prevalence and severity of subjective SE in children taking AEDs, proposing a 
scale for completion by the parents, the Hague Side-Effects Scale (HASES)." 
Items were contributed by child neurologists and parents of children using 
AEDs, and selected for the scale from a pilot pool on the basis of item analysis. 
The HASES comprises 20 symptoms relating to systemic toxicity and neurotoxic-
ity, which were common in a pilot population of children using AEDs. The in-
clusion of items in the HASES was based on empirical findings in this pilot study 
and not on clinical perceptions, although we felt the scale's content validity was 
satisfactory. The HASES was reliable in terms of internal consistency and retest 
stability.2~ 
V.le report the prevalence and severity of SE as measured using the HASES 
in children taking AEDs, and the association of the HASES score with clinical 
data. We focused on children with drug-resistant epilepsy. Patients with drug-
resistant epilepsy may be at risk for SE, because they often are treated with high 
dosages or multiple AEDs. The use of high dosages and multiple AEDs is gener-
ally believed to increase the prevalence and severity of SE. 2.~.n.t":I.Ql.1ll\ 
6.2 PATIENTS AND METHODS 
6.2.1 Design 
Children were recruited from the outpatient child-neurology departments of 
three University Hospitals, a Paediatric Hospital and a General Hospital. Eight 
child neurologists provided patients. Children with epilepsy were eligible when 
they were aged 4 to 16 years, were treated with at least one AED and had not 
been seizure-free for more than one year. The neurologists selected parents with 
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sufficient written Dutch language skills to be able to complete a questionnaire. 
Most first generation immigrant parents were thus excluded. 
A control group was selected of 25 age-matched children with asthma 
using only inhaled standard medication (corticosteroids and beta agonists) for 
this condition. It was hypothesized that such medication was unlikely to be 
causally related to SE as addressed in the HASES. 
The study protocol was approved by the Ethical Committees of the par-
ticipating centres. 
Scale 
The items addressed in the HASES are given in Table 6.1. All questions in the 
scale refer to symptoms attributed to the AED medication as recalled and per-
ceived by the parents, in the previous three months. Each item includes the fol-
lowing four response categories: 1. no problem or not applicable or cannot be as-
sessed because of impairment; 2. a mild problem; 3. a moderately serious prob-
lem; 4. a very serious problem. A simple scoring system was used, ranging from 
1 point (no problem or not applicable or cannot be assessed) to 4 points (very 
serious problem) for each item. Hence, for children with concomitant impair-
ments, it was possible that parents indicated that certain symptoms could be not 
applicable or could not be assessed. For example, when a child is unable to walk 
because of cerebral palsy, an AED cannot cause a disturbance of walking. In such 
children the impact of SE could thus be underestimated. On the HASES, the least 
severe score possible is 20 (indicating that none of the SE listed are perceived to 
be present), the most severe score 80 Call SE are very serious problems). To 
avoid investigator bias, parents completed the questions on the HASES at home. 
Parents were not instructed on how to interprete the meaning of items or re-
sponse categories. 
Clinical data and VAS 
The medical records of all patients were reviewed for information about the fol-
lowing variables: age, sex, classificationN and duration of epilepsy, time on pre-
sent AED regime, name(s) and dosage(s) of AED(s), and body weight. In the 
questionnaire including the HASES, the parents were also asked to report their 
child's seizure frequency or the duration of remission from seizures, respectively. 
Compliance was not formally assessed by a protocol of serum drug level tests, 
but the clinician was asked if he or she had reasons to believe that compliance 
was poor, yes or no. 
Because severity of SE will influence clinical decisions regarding medica-
tion, and because an objective assessment of the severity of SE as addressed in 
the HASES is lacking, we attempted to compare the parental ratings with the 
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neurologists' global evaluation of the severity of SE. The neurologist who treated 
the child rated the severity of SE on a IO-point Visual Analogue Scale (VAS)'''". 
ranging from I (no SE) to 10 (most severe SE imaginable). 
Association between HASES score and clinical data 
We examined three main hypotheses: 
1) HASES scores would be significantly higher in children on AED treatment 
than in children on anti-asthmatic medication. The latter medication is believed 
to be only rarely associated with SE as addressed in the HASES." 
2) HASES score would be higher in children on poly therapy than on mono thera-
py. The common opinion in the literature is that poly therapy is a risk-factor for 
SE. 
3) HASES scores would be positively correlated with relatively high dosages of 
an AED. Because children were using many different AEDs or combinations of 
AEDs, we computed a standardized dosage ratio. Average daily maintenance dos-
ages (DMDs) in the study group were computed per AED in mglkg. To be able to 
make comparisons between AEDs, we calculated the ratio of the prescribed DMD 
and the average DMD for each child. 'Ne subsequently computed the correlation 
between the HASES score and this ratio. Because the possibility of dnlg interac-
tions makes it difficult to compare mono- and poly therapy dosages, we first ana-
lyzed the children on mono therapy alone. Subsequently, we performed the same 
analysis including the children on poly therapy, using the summated ratio of the 
different AEDs. A comparable approach was described in a previous study in 
adults on side-effeclS of AEDs." 
Furthermore, we examined the correlation of the HASES score with age, 
sex and duration of epilepsy. A lack of association would be supportive of the 
HASES' validity, as there is no logical reason for an association with these 
sources of variation. The neurologists' VAS rating was compared with HASES 
scores, as a simple quantification of the clinicians' opinion and not as a 'gold 
standard'. Finally, differences in HASES score were determined between children 
with normal intelligence versus mentally retarded children, because in retarded 
children especially cognitive and behavioural SE can easily be missccLllll V>le com-
pared scores between children with and without noticeable seizures in the past 
three months, because the effects of recurrent seizures may be difficult to sepa-
rate from SE. 3<.'.1l3 And we compared scores between children on a steady state 
AED regimen verSHS children with a new AED or increased dosage within 90 
days before completion of the scale, because many SE occur predominantly at 
the start of new m.edicationt<9, even when hypersensitivity reactions and other 
idiosyncratic SE are left out of consideration. 
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6.2.5 Analysis 
The statistical analysis was performed with standard nOll-parametric tests. For 
the analysis of correlations, Spearman's rank correlation coefficient was used. 
The Mann Whitney U test was used to examine group differences. 
6.3 RESULTS 
We selected 117 parents for the study, 115 parents completed and returned the 
questionnaire. The questionnaire was completed by the mother in 52, the father 
in 6, both parents in 54 and other primary caretakers in 3 cases. Demographic 
and clinical characteristics of the children are listed in Table 6.2. 97 Children 
(84%) had recurrent seizures for more than one year despite state-of-the-art 
treatment with AEDs. The epilepsy classification was dominated by symptomatic 
epilepsies. Almost half of the children were mildly to severely retarded. Only 26 
children (23%) had been seizure-free in the previous three months. Only 2 chil-
dren were judged to be noncompliant to the prescribed AED regimen. These 
children were not excluded. 
SE (a score of more than 20 on the HASES) were reported in 94 children 
on AEDs (82%). Items obtained affirmative responses in 8% (double or blurred 
Vision) to 49% (fatigue) (see Table 6.1). Fig 6.1 shows the range and skewed dis-
tribution of scores of the 115 children on AEDs. The median HASES score in 
children taking AEDs was 26. 
60 
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Figure 6.1 Distriblltion of score frequencies on tile Hague Side-Effects Scale (HASES) 
in 115 children. Score rallge: 20 (least severe score, /lOlle of tlte ({sted Side-effects is a 
problem) to 80 (most severe score possible, all 20 Side-effects listed are VCl)' serio liS 
problems). 
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In the control group of 25 children wiLh asthma, 22 (88%) reported one or 
more SE on the HASES, scores ranged from 20 to 43, and the median was 22. 
Median HASES score was not significantly different between children with 
epilepsy and asthma (Mann-Witney U test, p = 0.15). 
Table 6.3 shows the distribution of AEDs and dosages. In 46 children poly-
therapy was used. The benzodiazepines and vigabatrin were (almost) exclusively 
prescribed in poly therapy regimens. As shown in Table 6.4, the ratio between 
prescribed DMD and mean DMD was generally lower [or children on l11onothera-
pyas compared to children on poly therapy. Mono- and poly therapy groups were 
well matched with respect to age and gender. Duration of epilepsy was signifi-
cantly longer in the children on poly therapy (mean 6.S years) than 011 monother-
apy (mean 3.4 years) (Mann-Whitney U test, p < 0.001). 
The difference in HASES score between children on mono- and poly therapy 
was not significant (Table 6.5). HASES score was not associated wiLh gender, 
mental retardation, being seizure-free for more than three months, or being on a 
stable AED regimen during the previous three months (Table 6.5). 
No significant correlation between dosage and the HASES score was found 
either in the monotherapy or in the entire group, including the children on poly-
therapy (Table 6.6). Age and duration of epilepsy did not correlate significantly 
with the HASES score (Table 6.6). 
The VAS score, reflecting the neurologist's perception of the severity of SE, 
did not correlate significantly with the parents' score on the SE scale (Table 6.6). 
A VAS score of 0 or 1 (indicating no or almost no SE) was given to only 17% of 
the sample. The median VAS score showed a significant difference between 
mono- and poly therapy groups (Mann Whitney U test, p = 0.005). Furthermore, 
the VAS score correlated significantly with the prescribed DMD/mean DMD ratio 
in the total group, but this correlation was not very strong (Spearman r = 0.27, 
P = 0.014). 
6.4 DISCUSSION 
The percentage of children taking AEDs reported to have SE ranges between 
about 50 and 75% 25).112, although in about 10% only, SE are considered intolera-
ble.55,!(\\\ll Hence, the majority of reported symptoms attributed to the use of 
AEDs are probably mild and clinically acceptable. Drowsiness/sleepiness, fatigue 
and decreased concentration were the most frequently reported SE, which was in 
accordance with, for example, results o[ Verity et aIm, and supported our impres-
sion that the HASES has sufficient content validity. 
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In our study, parents reported subjective SE in more than 80% of their 
children. This equals the results of a large European study using a comparable 
(self-report) scale for adulls taking AEDs; in this stud), 88% reported SE. D The 
use of a standardized questionnaire such as the HASES may account for the high 
percentage reporting SE, as a global, unspecified question may be less sensitive. 26 
However, most children in our sample had a severe epilepsy in terms of resis-
tance to AEDs. It is possible that the prevalence and severity of SE correlate with 
the extent to which seizures are drug-resistant: Drug-resistance may lead to high-
dose mono therapy 'pushed to toxicity' or the use of a combination of AEDs. 
Thus, we examined if the HASES score was associated with the number and 
dosages of AEDs. 
First of all, we found that poly therapy was not associated with a higher 
HASES score than monotherapy. However, in this observational study poly thera-
py may have been used only by children who tolerated it well. Further studies 
using the HASES in a blind, randomized comparison of mono- and poly therapy 
could solve this issue, which is sufficiently important to warrant further investi-
gation. Recently, after more than a decade of general preference for mono thera-
py, some have advocated the use of 'rational poly therapy' with newly developed 
AEDs, and it is possible that in the future specific polylherapy regimens will be 
used more often and earlier in the course of treatment. 
Alternatively, it is possible that not the number of AEDs but their (cumula-
tive) dosages are associated with the severity of SE: high-dose Ill.onotherapy regi-
mens may be as toxic as combinations of several AEDs in a low dosage. For this 
reason the relation between the dosage and HASES score was studied. Mean 
DMDs of each AED were in agreement with usual guidelines.-! We did not find a 
simple relationship between dosage ratios and BASES score. In children on 
monotherapy we found no Significant correlation between the dosage of an AED 
and the HASES score. Lammers et alt>~ provided some evidence for a relationship 
between AED dosage and the severit), of SE, but onl), in adults on pol)'therap)'. 
Using a comparable approach in children on mono- and poly therapy, we found 
no such relationship. Again, the observational design of onr stndy may have bi-
assed onr findings, as high dosages may have been prescribed only to children 
who seemed to tolerate them well. vVe are aware that widely different drug 
dosages may result in similar serum drug levels, and vice versa. 'rVe were not able 
to compare onr data regarding SE with senUll drug levels because for most chil-
dren, recent values were not available. 
\Ve anticipated and found no relationship between age and sex and the 
HASES score. Duration of epilepsy was related to the number of AEDs used, but 
not to the HASES score. A new AED or increased dosage within the last three 
months was not associated with a higher HASES score. Hence, we found no evi-
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dence for tolerance to SE as addressed in the HASES. Furthermore, we found no 
significant difference between children with normal intelligence and retarded 
children, with respect to the SE score. Thus, we found no evidence that SE in re-
tarded children were underreported, or that the symptoms and signs reported as 
side-effects were part of an underlying encephalopathy. v..'e found no evidence 
for confusion between SE and effects of (subtle) seizures, but the number of 
seizure-free children was small and we have not included EEG-monitoring to ex-
clude 'subclinical' seizures in children who were seizure-free according to their 
parents. 
Both the neurologists and the parents reported SE in > 80% of the children. 
However, the neurologist'S VAS rating correlated poorly with the parents' score 
on the HASES. This does not, by itself, suggest that the HASES is not a valid tool 
for the quantification of the parents' opinion, or disprove a causal relation be-
tween parent-perceived SE and the use of AEDs. Furthermore, it makes it likely 
that the HASES contributed new information for the clinician. An interesting 
finding was that the neurologists' VAS rating of children on poly therapy was sig-
nificantly higher than of children on monotherapy, and correlated with AED 
dosage. Although there is a possibility that the VAS rating by the neurologists in 
our study has a better discriminative ability than the HASES scale, an alternative 
explanation is that the neurologists were biased by the number and dosage of 
AEDs prescribed, for which they nor the parents were blinded. 
Even if one accepts our claim that the HASES is a valid and reliable instru-
lllent to quantify the parents' opinion about SE, a clinician will need to know if a 
high score only points to parental concenl or if it means that the dosage of AEDs 
needs to be adjusted. In the present study, a causal relationship between reported 
SE and the use of AEDs could not be established. 'We have not been able to in-
clude a control group taking placebo. It is well known that placebo's cause SE as 
well as pharmacologically active drugs. 'Ne have not included a control group of 
children not taking any medication, because our questionnaire specifically asks 
parents to report side-effects of medication, and not general signs or symptollls. 
However, the symptoms listed in the HASES are probably prevalent also among 
children who do not take medication and 'adverse nondrug reactions' have been 
noted in healthy, un medicated adults.~l The reported SE may be an effect of the 
chronic illness itself on the parents' perceptions. The lack of a significant dif-
ference in BASES median scores between the children taking AEDs and children 
receiving anti-asthma medication showed, at least, that the reported SE were not 
specific for children on AEDs. In a study by Austin et al ll using a global 7-point 
scale to assess 'problems with SE', mothers reported more SE in children on anti-
asthma medication as compared to children on AEDs. 1£ this were true, our find-
ings suggest that the HASES is more sensitive to SE associated with AEDs than 
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anti-asthma medication. Finally, some authors have suggested that a list of pos-
sible SE -such as the HASES- may actually cause SF'\ and others have not con-
firmed such an 'adverse effect ofinfonnation'.b~ It is unclear, how these studies of 
adult self-reported SE relate to parental report of SE as in our study. 
The subjective cognitive and behavioural SE addressed in the HASES were 
highly correlated with the other SE." Especially cognitive and behavioural SE of 
AEDs are an area of concern to clinicians. 30 However, after reviewing the lit-
erature, Vermeulen and Aldenkamp concluded that there is no convincing evi-
dence that AEDs in therapeutic dosages actually cause such SE. ll3 In children, the 
impact of AEDs on formal tests of higher cognitive functioning is probably limit-
ed.:> It would, nevertheless, be of interest to compare the HASES with formal 
neuropsychological assessments, if only to find out if the HASES could be useful 
as a screening tool to select candidates for formal testing. However, in adults, 
standardized neuropsychological assessments were poorly associated with subjec-
tive complaints.n~ Furthermore, such tests are not always appropriate for young 
or retarded children. 
Many new AEDs are marketed with a claim that they cause less SE than the 
traditional AEDs and we may anticipate a tendency to accept fewer -subjective-
SE for children taking AEDs in the future. SE of AEDs v;rill no doubt continue to 
be an area of concern to parents and clinicians. In clinical practice, the HASES 
seems useful as an easily administered, reliable and very sensitive tool to quantify 
the parents perceptions regarding subjective SE in a standardized way. 
Acknowledgements 
These investigations were supported by the Dutch National Epilepsy Fund, pro-
ject-number A 108. The authors are indebted to the following child neurologists 
for providing patients and clinical information: c.E. Catsman-Berrevoets, LA.E-
.M. L1an, O. van Nieuwenhuizen and R.].H.M. Gooskens. 
--- 83 ---
SUBJECTIVE SIDE-EFFECTS OF AEDs 
Table 6.1 Items addressed in the Hague Side Effects scale and responses by 
parents of 115 children taking antiepileptic drugs 
Items 
I. drowsiness/sleepiness 
2. dizziness 
3. uncertainty when walking 
4. falling 
5. sickness 
6. difficulty with defecation 
7. diarrhoea 
8. shaking, trembling 
9. speech difficulties 
10. double or blurred vision 
II. headache 
12. fatigue 
13. loss of appetite 
14. depression 
15. hyperactivity 
16. tcmpcr tantrums, aggression 
17. slowness 
18. poorer school results 
19. decreased concentration 
20. behavioural disturbance 
--84--
Number (%) of 115 chi Idren 
reported to have a mild to very 
serious problem 
48 (42%) 
16 (14%) 
13 01%) 
lO (9%) 
19 (16%) 
1806%) 
11 00%) 
1705%) 
14 02%) 
9 (8%) 
40 (35%) 
56 (49%) 
29 (25%) 
15 (13%) 
34 (30%) 
38 (33%) 
55 (39%) 
39 (34%) 
51 (44%) 
25 (22%) 
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Table 6.2 Demographic and clinical variables of 115 children taking antiepileptic 
drugs 
Mean age (SD) 
Sex 
Mean duration of epilepsy (SD) 
No seizures in previous 3 months 
Epilepsy classification 
Number of AEDs per patient 
Mental retardation 
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10.1 (3.4) years 
61 (53%) boys 
4.7 (3.8) years 
26 (23%) 
I oca I i zat i all-related 
- idiopathic with age-
related onsel: 13 (11%) 
- s)"nptomatic: 47 (41%) 
generalized 
- idiopathic with age-
related onsel: 24 (21%) 
- symptomatic: 23 (20%) 
IIllclassified: 8 (7%) 
1 AED: 69 (60%) 
2 AEDs: 30 (26%) 
3 AEDs: 15 (13%) 
4 AEDs:I (1%) 
47 (41%) 
Table 6.3 
AED 
Valproate 
Carbamazepine 
Phenytoin 
Ethosuximide 
Clobazam 
Clonazepam 
Nitrazepam 
Vigabatrin 
Phenobarbital 
Oxcarbazepine 
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Number of children taking an AED, mean daily maintenance dosage 
(DMD) and range of dosages in mg/kg (N = 115) 
Monotherapy Mono- and polytherapy 
N DMD Range N DMD Range 
(mg/kg) (mg/kg) 
23 21.7 (9.3) 8.0-39.0 52 23.8 (l0.!) 2.4-43.5 
27 13.0 (4.8) 5.3-27.3 52 15.7 (6.0) 5.3-28.6 
5 6.1 (1.7) 3.5-8.0 14 6.6 (1.8) 3.5-9.2 
4 23.2 (3.4) 20.0-27.8 8 21.2 (3.3) 17.4-27.8 
0 9 0.52 (0.5) 0.18-1.9 
0 4 0.05 (0.03) 0.02-0.08 
0 2 0.58 (0.14) 0.44-0.72 
3 50.7 (21.9) 32.6-75.0 21 42.002.6) 22.7-75.0 
2 9.2 (6.7) 4.4-13.9 3 6.8 (6.3) 2.0-13.9 
5 33.5 04.6) 11.8-48.7 9 31.8 (l2.!) 11.8-48.7 
DMDs are means (SD). 
Note: 46 children were on poly therapy. Rescue medication was not included in 
the study. 
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Table 6.4 Distribution of number of children over prescribed DMD/mean DMD 
ratios and relation with number of AEDs 
ratio 
0.01-0.33 
0.34-0.66 
0.67-1.00 
1.01-1.33 
1.34-1.66 
1.67-2.00 
2.01-2.33 
2.34-2.66 
2.67-3.00 
3.01-3.33 
3.34-3.66 
3.67-4.00 
4.01-4.33 
4.34-4.66 
>5.00 
All 
N=115 
0 
16 
25 
20 
10 
11 
6 
8 
6 
6 
4 
0 
0 
2 
I 
Monotherapy 
N=69 
0 
15 
24 
18 
8 
3 
1 
0 
0 
0 
0 
0 
0 
0 
0 
DMD, daily maintenance dosage (in mglkgl. 
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Polytherapy 
N=46 
0 
1 
1 
2 
2 
8 
5 
8 
6 
6 
4 
0 
0 
2 
I 
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Table 6.5 Comparisons of scores on the HASES between groups 
(Mann Whitney U test) 
N Median 
girls 54 26 
boys 61 25 
mono therapy 69 25 
poly therapy 46 26.5 
normal intellect 68 26 
mental retardation 47 25 
seizure-free >3 months 26 25 
not seizure-free 89 26 
>90 days unchanged AED 61 25.5 
New AED/increased dose 54 26 
HASES, The Hague Side-Effects scale 
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p 
0.56 
0.16 
0.95 
0.32 
0.85 
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Table 6.6 Correlation of score on the HASES with clinical variables 
(Spearman r, N = 115) 
r 
Prescribed DMD/mean DMD Cmonotherapy) -0.11 
Prescribed DMD/mean DMD Call children) 0.12 
Age -0.05 
Duration of epilepsy 0.17 
Neurologists' severity of SE score * 0.18 
p 
0.38 
0.21 
0.56 
0.08 
0.12 
HASES, The Hague Side-Effects scale; SE, side-effects; DMD, daily maintenance 
dosage of an antiepileptic drug (in mglkg). * On a lO-point Visual Analogue 
Scale. 
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7.0 SUMMARY 
Parents and doctors impose restrictions on children with epilepsy to avoid 
seizure-related injuries. We intended to quantify disability due to such restric-
tions by using a newly developed parent-completed lO-item scale (The Hague 
Restrictions in Childhood Epilepsy scale, HARCES). Parents reported disability 
on at least one item of the HARCES in 83% of 122 children with epilepsy and a 
remission from seizures for less than one year. Psychometric analysis of the 
scale's reliability demonstrated good internal consistency and retest stability. Its 
validity was supported by the association between HARCES scores and the physi-
cians' advice to impose restrictions. We found no substantial association with 
such variables as seizure type, short-term remission, or seizure activity. These 
findings suggest that in children with recurrent seizures, restrictions were proba-
bly not optimally adapted to seizure-related risks. A repeat test after one year 
showed that a seizure remission of more than one year substantially reduced 
restrictions, which is probably associated with an improvement in quality of life. 
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7.1 INTRODUCTION 
Parents impose restrictions on their children with epilepsy to reduce the 
risk of seizure-related injuries and they are often aclviced to do so by the treating 
physician. There is no doubt that such restrictions can adversely influence the 
development of children with epilepsy"". Clearly, for a child to lead a life as nor-
mal as possible, the 'pros and cons' of restrictions should be carefully balanced. 
The optimal balance, however, is hard to find, if only because little is known 
about the specific risks nlll by children with various forms of epilepsy and con-
comitant disorders. Because restrictions limit the child's ability to perform ac-
tivities of daily life (ADL) in the manner or within the range considered normal 
for the child, they may cause disabilities as defined by the World Health 
Organization (WHO)ll2 -see Table 7.1 for definitions. 
Disabilities in children with epilepsy can sometimes be related to impair-
ments (see Table 7.1) e.g. mental retardation or cerebral palsy, but most children 
with epilepsy have no such impairments. SillanpM ON reported that children ,vith 
epilepsy had more disabilities than a control group. Disability was associated 
with impairments due to neurological comorbidity. For children without such 
impairments the difference from the control group in overall occurrence of dis-
abilities was not significant. In the same study, however, all families subjectively 
experienced their child as disabled. We were interested to learn more about the 
relationship between the epilepsy itself and disability in children. 
We developed a scale to quantify parent-perceived disability due to restric-
tions in childhood epilepsy and explored its association with various clinical 
variables, which we selected because we assumed they were associated ,vith 
seizure-related risks. 
7.2 METHODS 
7.2.1 Content 
We developed the Hague Restrictions in Childhood Epilepsy Scale (HARCES) in 
the following steps. First of all, 35 parents of children with epilepsy were asked 
to list the daily life activities which were limited by their child's epilepsy. Parents 
were instructed to focus on disabilities caused by the epilepsy, and to discount 
disabilities caused by other factors, such as mental retardation or cerebral palsy. 
A lO-item scale was developed, based on the parents' suggestions and a review of 
items by the participating neurologists. h was felt that most of the suggested 
items pertained to restrictions to avoid seizure-related injuries or other adverse 
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effects of seizures. Some items (addressing specific precautions and activities like 
swimming, riding a bicycle or physical excercise) were considered to be quite 
specific to epilepsy, other items seemed applicable to other childhood disorders 
as well (e.g. restrictions against 'stayring] the night with friends or relatives'). 
This lO-item scale included two global items: one for the amount of extra 
supervision needed and one for special precautions taken (such as wearing a hel~ 
met or special bathing cap), and addressed eight specific activities of daily life. 
The full scale is listed in Table 7.2. Each item has four adjectival response cate-
gories providing a score of 1 (most favourable) to 4 (most unfavourable) points 
per item. The HARCES' total score ranges from ]0 (no disabilities) to 40 (most 
severe disabilities), 
Patients and parents 
Children and their parents were recruited from the outpatient populations of the 
deparunents of child neurology of two hospitals in The Hague (a children's hos-
pital and a general hospital) and the University Hospitals of Rotterdam, Leiden 
and Utrecht. 
We selected children aged 4 to 16 years with a diagnosis of epilepsy who 
had suffered at least one seizure in the previous year. Physicians were asked to 
recruit parents with sufficient Dutch reading skills to complete a questionnaire. 
Consequently, most first-generation immigrant parents, whose children were eli-
gible, were excluded. Parents completed a mailed questionnaire at home. The 
questionnaire included the HARCES scale, the l'Iague Seizure Severity scaleu" and 
single items addreSSing duration of remission, estimated likelihood of a seizure 
occurring in the next month, patterns of timing and predictability of seizures, 
and parentalleve1 of concern about the child's epilepsy. All questions referred to 
the situation in the preceding three months. 
The medical records of aU patients were reviewed for information on the 
duration of epilepsy, treatment and compliance, mental retardation or cerebral 
palsy, and educationalleve1 (five categories of schools reflecting different levels 
of intellectual ability were used, ranging from normal schools to day-care centres 
for severely retarded children). The child's regular neurologist was asked if 
restrictions had been advised and to claSSify seizures and epilepsy according to 
the current ILAE classificationslS.l'l. 
One hundred and twenty-four (124) parents were asked to complete the 
scale and the additional questionnaire, including the 35 parents who had partici-
pated in the pilot phase. The 87 parents of the children who had not been in-
volved in the pilot testing phase, were sent a second questionnaire after one year, 
which was identical to the first and thus allowed for a repeat test comparison. 
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Psychometric analysis of the scale 
Psychometric analysis included item-analysis, assessment of internal consistency 
and retest stability. We computed corrected item-total correlations (CITCs) and 
frequency distributions of answers. Crohnbach's alpha was computed as a mea-
sure of the scales' internal consistency. A scale has sufficient internal consistency 
for research purposes, when alpha is at least O.SIre. Furthermore, test-retest sta-
bility was assessed. Of 22 consecutive parents, 18 responded to an invitation to 
complete a repeat questionnaire 14 days after they had completed the first. 
Statistical analysis 
Because HARCES' scores were not normally distributed, standard non-parametric 
statistical methods were used. A significance level of p <0.01 was chosen to re-
duce the chance of a type I error because multiple comparisons were made. 
Spearman's "s was used as a measure of correlation. The Mann Whitney U test or 
Kruskal-Wallis one-way analysis of variance (with correction for ties) were used 
to compare group differences. To analyze differences between repeated measures, 
the Wilcoxon matched-pairs signed-ranks test was used. 
7.3 RESULTS 
Of 124 parents, 122 (98%) returned the questionnaire. Overall availability of 
data was excellent, and parents had no serious problems when ~ompleting the 
questionnaire. 
7.3.1 Psychometric analysis of the HARCES 
CITC's ranged from 0.44 to 0.82 and items produced affirmative responses in 
25% (playing indoors) to 65% (swimming) (see Table 7.2 for a complete listing 
of responses). Alpha of the scale was 0.89. Retest "s after 14 days was 0.93 
N=18). 
Figure 7.1 (on the next page) shows the skewed distribution of the scores. 
The median score was 16.0 and the scores ranged from 10 (in 21 children, re-
flecting no disability) to 35 (in two children, reflecting severe disability). Hence, 
in 101 of 122 (83%) children parents reported disability. 
--- 95 ---
DISABILITY DUE TO RESTRICTIONS 
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HARCES score 
Figure 7.1. Distri"utioll of score frequellcies all the HARCES ill 122 childwl. 
Scale range: 10 (least severe) to 40 (most severe score possible). 
7.3.2 HARCES score and clinical variables 
The majority of children included had a long history of epilepsy without remis-
sion and only 20 children had had epilepsy for less than one year (see Table 7.3 
for demography and clinical variables). Only a few were not taking AEDs and 
more than one third were receiving poly therapy. Only two children were judged 
non-compliant with the prescibed AED regimen. 
The results of a univariate analysis of the association between the score and 
clinical variables are shown in Table 7.4. Two factors were significantly associat-
ed with the disability score. \Vhen the neurologist had advised imposing restric-
tions, the median score was higher than when this was not advised (median 18 
vs 13, p <0.00l). Parent-estimated likelihood of a seizure occurring in the next 
months was Significantly, but not very substantially, associated with the score 
(rs~ 0.28,)1=0.002). The correlation between 'advice' and 'likelihood of seizure' 
was also not very substantial ('-s= 0.23, p=O.035). No significant influence was 
found for any of the other clinical variables. The difference in HARCES score be-
tween children with seizures for less than one year and more than one year was 
not significant ()1=0.77). 
The parents' own judgement of their 'level of concern about their child's 
epilepsy' was Significantly correlated with the HARCES score (rs~ 0.42, 1'<0.001). 
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Repeated HARCES after one year 
Of the 87 children selected for a repeat test after one year, one child had died, in 
one child the diagnosis of epilepsy had been rejected, and three were lost to fol-
low-up. Thus, 82 parents were asked to complete a second questionnaire, and 78 
(95%) responded. At the time of the second questionnaire, 51 children had suf-
fered recurrent seizures without remission, 13 had achieved a remission between 
three months and one year and 14 had achieved a remission of> one year. 
Overall, the correlation between the first and second HARCES score was 
high (rs :=:0.75). There was no trend towards a lower or higher score after one 
year (Wilcoxon matched-pairs signed-ranks lest, p=O.76; 27 repeat scores were 
higher, 25 were lower and 26 were equal). However, median scores on the 
HARCES were lower for children who had achieved a period of remission from 
seizures (> one year remission: median 11.5; remission> 3 months - 1 year: me-
dian 14; no remission: median 20, Kruskal-Wallis ANOVA, X2=11.7, p=0.003). 
7.4 DISCUSSION 
Our study demonstrated parent-reported disability due to restrictions in 83% of 
122 children with epilepsy and a remission ofless than one year. The fact that all 
children were attending outpatient child neurology clinics, does not suggest that 
they were suffering froIll unusually severe epilepsies. In the Netherlands, chil-
dren with epilepsy are not likely to be treated by a general practitioner. However, 
our sample included many children with epilepsy and a poor prognosis to 
achievc a complete remission within a short period, and is, therefore, represen-
tative only of a minority of a population-based sample of new onset epilepsies. 
Nevertheless, clinicians cannot predict the prognosis for quick and complete re-
mission for most children with new onset epilepsy with great confidence. They 
will advice imposing restrictions on Illost of them, when they perceive a substan-
tial risk of seizure-related injuries. In fact, we have not found a significant differ-
ence in HARCES scores between children with a history of less than and more 
than one year. To address the influence of a remission of morc than one year, we 
performed a follow-up study. 
The HARCES sca!e's reliability analysis demonstrated good internal con-
sistency and retest-stability. its validity was supported by its association with the 
physicians' advice to impose restrictions and lack of association with presence or 
absence of permanent impairments like mental retardation and cerebral palsy. 
These are well-recognized causes of disability which we did not intend to address 
with the HARCES. 
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The neurologists had advised imposing at least some restrictions in about 
two-thirds of the children. In these children, the median score on the HARCES 
was significantly higher than the median score of the remaining children. In our 
opinion, this finding emphasizes the responsibility of doctors when they counsel 
the parents about restrictions. The precise nature of the advise given, however, 
was not recorded; nor were the grounds on which the clinician based the advice. 
From a clinical point of view, restrictions imposed on children with epilep-
sy should relate to a child's individual risk profile. A child will be more at risk of 
getting injured due to a seizure when seizures are frequent, severe or unpredicta-
ble. Unfortunately, little is known about the specific risks associated with such 
clinical variables or the influence of age and impairments on seizure-related 
risks. 
Epidemiological studies assessing the risks of seizures in a population of 
children with epilepsy are rare. Beghi cl al. l7 reported no difference for everyday 
life risks between patients with epilepsy aged between 5 and 68 years and 
healthy controls. In multi-handicapped adults with epilepsy closely obsen'ed in 
nursing homes during 13 months, seizure related injuries were rare and mild, se-
rious injuries occurred in 0,09% of seizures and were related to atonic and 
generalized tonic-clonic (GTC) seizuresN • In children over 5 years of age with 
epilepsy, drowning accidents occurred more often than in the general 
populationH . Closer supervision may explain the lack of difference that was 
found in the frequency of submersion injuries in under 5-year-olds with and 
without epilepsy. 
Despite the lack of specific risk profiles, most authors H15{o,85.1(Ito.lO» agree 
about global guidelines of cOllncelling abom restrictions in childhood epilepsy. 
Activities for which restrictions are often advised are bathing, swimming, climb-
ing and riding a bicycle. Everyday life at home should not be restricted, except 
for children with especially dangerous types of seizures~. Participation in sports 
and physical exercise is generally not discouraged. Parents must set the standard 
of acceptable risk and make their own judgements about restrictionsl('O. Few au-
thors indicate how long a period of remission would be sufficient to reduce or 
totally discard previously imposed restrictions. Some have suggested a remission 
of at least two months for low risk activities such as riding a bicycle, and of two 
years for high risk activities Ill'!. However, children are unlikely to perform high 
risk activities, such as driving a car or risky sports, anyway. 
7.4.1 HARCES and clinical variables 
Although short-term remission (between three and twelve months) made no sig-
nificant difference on the HARCES score, a remission of> one year was asso-
ciated with a lower median score. These data suggest that parents and doctors 
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awaited a long period of remission before restrictions were discarded. They sup~ 
port that 'one year remission' is a relevant measure of outcome in clinical studies 
of childhood epilepsy, probably associated with an improvement in the childrens 
quality of life. The parents' (subjective) perception of the likelihood of a seizure 
occurring in the next month was also significantly associated with the score on 
the HARCES, but the association was not very strong ("5 0.28). We found no 
significant relationship between other a priori selected clinical variables and the 
HARCES score. 
Overall, differences in median HARCES score between seizure types were 
not significant, although the highest median score was found for atonic seizures. 
The risk of seizure-related injuries associated with such seizure types as ab~ 
sences, simple and complex partial seizures is probably much smaller than the 
risk associated with GTC or atonic seizures 79. The children with absences (with-
out GTC seizures) obtained a median score on the HARCES which came remark-
ably close to the median score of children with GTC seizures. It is not within our 
competence to judge whether this points to overprotection of children with ab-
sences, although some of these children, when they become adults, may state 
that their parents have overprotected themS6• Vve have not used seizure frequency 
as a variable in our study, because it is closely associated with seizure type: espe-
cially absences come in very high frequencies. However, in a study of children 
with epilepsy Austin et ai. 11 found that a score reflecting participation in social 
activities did not correlate with seizure frequency. 
It has been suggested that the age of the childH and presence of impair-
ments,I,'N may influence the necessity of restrictions. It is possible that young or 
severely retarded children are closely supervised anyway and more limited in 
their daily activities, and that therefore the impact of epilepsy is smaller in these 
children. '0le have not found an association between age or impairments and the 
HARCES score. \Ve have deliberately focused on disability caused by restrictions 
and not due to impairments. 
Vve found a significant correlation with an item addressing 'level of con-
cern', which at least suggests that further studies addressing the association be-
tween psychosocial variables and restrictions as measured using the HARCES 
may be fruitful. It is possible that the severity and nature of restrictions to some 
extent reflects the parents' anxiety or tendency to overprotect their children. 
furthermore, parents may impose restrictions simply because their child has a 
disorder, regardless of disease-specific risks. In a study by Austin et alY social 
activities' scores did not differ significantly between children with asthma and 
epilepsy. An extensive discussion of the psychosocial consequences of childhood 
epileps)' for the child and the famil), is be)'ond the scope of the present paper. 
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Suggested use of the HARCES 
In addition to the lack of knowledge about the risks nm by children with epilep-
sy, there is little information available about the efficac), ofimposed restrictions 
in preventing injuries or death, or about the child's compliance with imposed re-
strictions. Nevertheless, doctors advise imposing restrictions in most cases and in 
our study this advice was shown to have a significant influence on the parents. 
Counselling about restrictions to impose on children with epilepsy should proba-
bly be repeated at regular intervals in any child with epilepsy, as during the 
course of treatment symptoms may change or remission may be achieved. The 
HARCES can be useful to help optimize the balance between risks and 
overprotection. At all times clinicians must be aware that parents may find 
themselves in a 'catch 22' situationI2l and should never be accused of overprotec-
tion or negligence. 
We suggest the use of the HARCES as a measure of quality of life in studies 
of outcome in childhood epilepsy. We have developed similar subjective parent-
completed scales addressing seizure severity and severity of side-effects26• In our 
opinion these scales address three important issues in the physical domain of 
quality of life. There is increasing awareness that such measures of quality of life 
may contribute to a more differentiated outcome assessment in (childhood) 
epilepsy u;n.3~. Translated versions of the scales for severity of seizures, side-ef-
fects and restrictions are currently being validated in a United States population, 
including a comparison between the parents' and childrens perceptions83 • A preli-
minary analysis suggested that children felt less restricted than their parents felt 
they were restricting them. 
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Table 7.1 Definitions used in the study 
Impainnenl: Any loss or abnormality of psychological, physiological or anatomi-
cal structure or function. 
Disability: Any restriction or lack (resulting from an impairment) of ability to 
perform an activity in the manner or within the range considered normal for a 
human being. 
Handicap: A disadvantage for a given individual, resulting from an impairment 
or a disability, that limits or prevents the fulfilment of a role that is normal (de-
pending on age, sex, SOciH.l and cultural factors) for that individual. 
World Health Organization (1980).'" 
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Table 7.2 The HARCES and response percentages in 122 children 
The following questions are about the restrictions placed on your child because 
of the epilepsy. If, for example, your child can ride a bicycle, but is not allowed 
to, because of the chance of a seizure, we call it a restriction resulting from the 
epilepsy. If your child can't ride a bike because of some other reason, (eg. being 
too small, or having a handicap), it does not count as such. 
1. How much extra supervision is needed in your child's daily activities? 
a. a lot 
b. some 
c. a little 
d.none 
3 
12 
40 
44 
2. Does your child require special precautions in daily activities? 
(lilw wearillg a helmet! 
a. always 6 
b. usually 5 
c. sometimes 18 
d. never 71 
3. Does the epilepsy influence the freedom of your child to play in the house? 
(freedom means: the ability to do things ill the normal way of a child withollt 
epilepsy) 
a. a lot 
h. some 
c. a little 
d.notatall 
2 
4 
20 
75 
4. Does the epilepsy influence the freedom of your child to play outside? 
a. a lot 
h. some 
c. a little 
d.notatall 
4 
12 
30 
55 
5. Does the epilepsy influence the freedolll of your child to go swimming? 
a. a lot 
b. some 
c. a little 
d.notatall 
20 
22 
23 
35 
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6. Does the epilepsy influence the freedom of your child to participate in 
sports activities (excluding swimming)? 
a. a lot 5 
b. some 8 
c. a little 31 
d. not at all 56 
7. Does the epilepsy influence the freedom of your child in traffic 
(like riding a bicycle)? 
a. a lot 
b. some 
c. a little 
d. not at all 
12 
16 
19 
53 
8. Does the epilepsy influence the freedom of your child to stay 
elsewhere overnight? (withfricllcls D .. family) 
a.alot 10 
h. some 
c. a little 
d. not at all 
17 
23 
50 
9. Does the epilepsy influence the freedom of your child to go to parties? 
a. a lot 3 
h. some 
c. a little 
d. not at all 
11 
25 
62 
10. Does the epilepsy influence the freedom of your child to participate in 
physical education? 
a. a lot 
b. some 
c. a little 
d. not at all 
10 
8 
33 
49 
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Table 7.3 Demographic and clinical variables of 122 children 
Mean age (SD) 
Sex 
Mean duration of epilepsy (SD) 
Epilepsy classification 
AED treatment 
Mental retardation 
Other impairments 
10,1 (3,3) years 
(range 4-16 years) 
65 (53,3%) boys 
4,6 (3,8) years 
local i zat iOIl- re la ted 
- idiopathic with age-
related onset: 16 (13%) 
- symptomatic: 48 (39%) 
gelleralized 
- idiopathic with age-
related onset: 27 (22%) 
- symptomatic: 23 (19%) 
IIllclassified: 8 (7%) 
no AED: 7 (6%) 
1 AED: 69 (57%) 
>1 AEDs: 46 (38%) 
48 (39%) 
14 (12%) 
SD=Standard Deviation. AED= anti epileptic drug. 
Mental retardation was based on schooling level and was sometimes accompa-
nied by other impairments. 'Other impairments' refers to children without men-
tal retardation, in most cases cerebral palsy. 
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Table 7.4 Score on the HARCES: relation with clinical data in 122 children. 
Variable 
Clinical data: 
Seizure type' 
simple partial (n=l7) 
absences (n=18) 
complex partial (n=35) 
generalized tonic-donic (n=34) 
atonic (n=13) 
Duration of epilepsy 
Sex 
boys (n"65) 
girls (u"57) 
Age 
Neurologic impainncnts 
yes (n"58) 
no (n"64) 
Schooling level' 
Restrictions advised by neurologist 
no (n"39) 
yes (n"79) 
Parent qucstionlwirc: 
Predictability of seizures$ 
aura, useful as warning signal 
provoking factors (watching TV, lack of sleep) 
timing at fixed pan of day or night 
clustering of seizures 
Seizure control 
remission between 3 and 12 months 
yes (u"28) 
no (n"94) 
likelihood of a seizure in next month" 
Perceivcd seizure severity (scale) 
Test result Significance (P) 
X'" 5,00 0,29' 
mcrlian",12,5 
median=14 
median=l7 
rnedian=16 
median=19 
's" 0,18 0,05* 
Z",O,61 0,54@ 
rnedian=15 
median:::17 
rs=-O,03 0,74* 
Z",O,24 0,81@ 
rncdian:=16 
median=15 
Ts=-0,05 0,55* 
Z~,3,55 0,0004@ 
median=13 
rncdian:=18 
f s=O,OI 0,90* 
rs=0,08 0,44* 
's",O,08 0,47* 
's",O,08 0,48* 
Z",l,36 01Y@ 
median=15 
rnedian=16.5 
rs=O,28 0,002* 
's~0,16 0,13* 
'Most bothersome seizure type classified in 117 children (seizures were unclassified in 5 
children). 
~ Kruskal-\Vallis analysis of variance with correction for ties. 
, Spearman Rank Correlation (rs)' 
G Mann-\Vhitne)' U Test. 
, Five categories of schools, reflecting intellectual ability. 
, Single items with four subjective answering categories. 
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A brief sUIllmary of chapters 2-7 will be presented here, more extensive 
summaries can be fonnd at the beginning of each chapter. Some concluding re-
marks are made, with suggestions for further studies. 
Chapter 2 described a study based on the material of the Dutch Study of 
Epilepsy in Childhood (DSEC), following 494 children with newly developed 
epilepsy. It addressed the treatment strategies adopted by the participating child 
neurologists. In this cohort, two years after inclusion, 17% of the children with 
new onset epilepsy were not receiving treaUncnt with AEDs. The impact of seiz-
ures in these children was probably limited and did not outweigh the possible 
adverse effects of treatment with AEDs. Treatment was initially withheld in 29% 
of the cohort; hence, in about half the children this 'wait-and-see' policy seems to 
have failed during the follow-up period. After two years, the first AED regimen 
had not provided acceptable control of seizures or had caused unacceptable side-
effects in 40% of the children. Finally, about 10% had not achieved a substantial 
remission from seizures. \Ve noted that in 15 of these 50 children who suffered 
recurrent seizures despite treatment with AEDs, the neurologist indicated that 
'acceptable control' had been achieved. 
These findings raised at least two questions: I. Vlho judged whether the 
impact of seizures was acceptable or not, and, if not, who judged whether (more 
or different) AEDs were indicated to suppress seizures: the child, the parents or 
the doctor? 2. \Vhat were the motives for considering seizures and side-effects to 
be sometimes acceptable and sometimes not? The material of the DSEC, which 
included traditional outcome variables only, did not provide answers to these 
questions. They confirmed that a more complete approach towards outcome as-
sessment in childhood epilepsy, including measures of subjective disease severi-
ty, may be rewarding. Clearly, it is important to monitor more than 'objective' 
variables like seizure frequency or duration of remission, or clinically intolerable 
side-effects. Chapters 3 to 7 describe our efforts to develop tools for this pur-
pose. 
In chapler 3, we reviewed scales which were developed by others to im-
prove outcome assessment in epilepsy. In their present form, these scales for 
adults with epilepsy seemed inappropriate for children. Some basic differences in 
methodology between the scales were discussed. Physical issues, such as 'severity 
of seizures and side-effects' were identified as neglected areas in quality of life re-
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search. We outlined the problems developing similar measures of outcome for 
children with epilepsy. 'We explained why we selected the parents as the source 
of information and not the child itself. 
Cllal'ters 4 and 7 describe the development of three scales addressing, 
respectively, 
(1) Seizure severity (the Hague Seizure Severity scale, HASS). We used one of 
the reviewed scales for adults, the Liverpool Seizure Severity scale IS, as a 
basis for the development of this scale; 
(2) Severity of side-effects of AEDs (the Hague Side-Effects scale, HASES); 
(3) Severity of disability due to restrictions to avoid seizure-related injuries in 
children ,,~th epilepsy (the Hague Restrictions in Childhood Epilepsy scale, 
HARCES). 
An three scales were developed using items contributed by neurologists as well 
as parents. The scales comprise subjective items to be completed by the parents. 
Because these scales reflect a broad approach towards outcome assessment in 
childhood epilepsy and because they quantify subjective perceptions rather than 
objective asseSSIIl.ents, they can be classified as quality of life insu·uments. 
Nevertheless, they focus on clinical issues and should not be regarded as mea-
sures of overall quality of life or psychosocial outcome. A description of the psy-
chometric analysis of the HASS and the HASES can be found in chapter 4, and of 
the HARCES in chapter 7, respectively. All three scales were reliable in terms of 
retest stability and intenlal consistency. Further studies included an assessment 
of the validity of these scales, especially by comparing them with clinical data. 
In chapters 5 alld 6, respectively, the HASS and the HASES are compared 
with clinical data, including the clinicians' global impressions of the severity of 
seizures and side-effects. Ratings of the parents and neurologists were not sub-
stantially correlated. Scores on the HASS were Significantly different between var-
ious seizure types, but \vithin one seizure type considerable variation in reported 
seizure severity was noted. Scores on the HASES did not differ significantly be-
tween children taking medication for epilepsy or asthma. We noted no difference 
in the severity of side-effects as addressed in the HASES between children receiv-
ing mono- or poly therapy, nor was there a correlation between dosage of AEDs 
and score on the HASES. 'Vole have not been able to confirm the validity of the 
HASES as a measure of side-effects, possibly due to limitations in our study de-
sign. The practical importance of the parents subjective assessments of side-ef-
fects, however, would seem to justify further controlled studies using the HASES. 
In chapter 7, the HARCES is compared with clinical data. \Ve describe a 
lack of influence of various clinical variables on restrictions as addressed in the 
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HARCES. Only a remission from seizures of more than one year was associated 
with a significant reduction in HARCES score. 
One of the core messages of the chapters 5-7 is that these three scales add 
Ilew information to traditional clinical data as well as the clinician's global im-
pressions. Trials comparing AEDs typically yield equivocal results, and a broader 
assessment of outcome, e.g. by using the present scales, could be helpful. The 
usefulness of these scales for trials and clinical practice, however, still has to be 
established. 
V-le need to assess sensitivity to (clinically relevant) change. In a follow-up 
study of children with recurrent seizures, we found no significant difference in 
seizure severity after one more year of therapy.m It is more likely that this find-
ing points to the intractable nature of the seizures in this sample, rather than to 
insensitivity to change of the l-LASS. For this purpose, use of the scales in clini-
cals trials is being planned. 
Furthermore, we are hopeful that our scales will prove to be useful in guid-
ing or clarifying management decisions in the treatment of children with epi-
lepsy, and, thus, be of help in answering some of the questions raised in 
Chapter 2. As such, the scales could be of use to clinicians in daily practice. For 
example, would it be possible to optimize the balance between risks and restric-
tions for children with epilepsy by using the HARCES as a basis for discussion 
and follow-up? 
Another interesting question is how the parents' perceptions relate to those 
of their children. This is one of the goals of a study in the USA, which uses a 
translated version of our scales.s3 A preliminary analysis showed that parents' and 
childrens' perceptions were highly correlated, although children felt, in fact, less 
restricted than their parents believed they were restricting them. The second aim 
of this American study is to validate the English versions of the scales. 
At present there is increasing interest in quality of life scales for epilepsy. 
We have developed the scales described in this thesis hoping that they will be 
used outside our own institutions. Therefore, we would stimulate initiatives from 
other researchers to use them. Copies of the scales will be provided on request; 
an (American) English version is available. 
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9 SAMENVATTING EN CONCLUSIE 
Hieronder wordt een samenvatting gegeven van de volgende hoofdstukken uit dit 
proefschrift, gevolgd door een korte discussie: 
Hoofdstllh 2: Een audit van behandelingsstrategie bij een groep kinderen bij wie 
de diagnose epilepsie voar het eerst wordt gesteld. 
HooJdstllh 3: Een overzicht van de literatuur met be trekking tot alternatieven 
voor de traditionele uitkomst-variabelen. 
HooJdstllll 4: De ontwikkeling en psychomctrische analyse van schalen voor de 
'ernst van aanvallen en bijwerkingen van anti-epileptica' (AEDs). 
HooJdstuh 5: De relatie tusscn 'ernst van aanvallen' en diverse klinische 
varia belen. 
HooJdstull 6: Dc rclatk tussen 'ernst van bijwerkingen' en diverse klinische varia-
belen. 
HooJdstuh 7: De ontvvikkeling en psychometrische analyse van een schaal voor 
'ernst van bcperkingen door epilepsie'. De relatie tussen deze schaal en diverse 
klinische variabelen. 
9.1 Hoofdstuk 2: 
AUDIT VAN BEHANDELING VAN KINDEREPILEPSIE. 
Dit hoofdstuk beschrijft de behandeling van epilepsie bij 494 kinderen uit 
het Zuid-Hollandse Kinderepilepsie Onderzoek (ZHKO). Van dit cohort werd 
aanvankelijk 29% niet met medicijnen behandeld, en na twee jaar was het per-
centage onbehandelde kinderen nag 17%. Bij deze kinderen waren de te ver-
wachten gevolgen van de aanvallen dus kennelijk zo gering, dat zij niet opwogen 
tegen de verwachte bijwerkingen van AEDs. Ongeveer 40% van de kindercn met 
epilepsie moest stoppen met de medicatie van eerste kens, hetzij omdat de aan-
vallen onvoldoende werden onderdrukt, hetzij omdat de bijwerkingen onac-
ceptabel waren. Na twee jaar had ca. 10% van de kinderen met medica tie geen 
langdurige remissie van aallvallen bereikt. \Vij vonden aanwijzingen dat bij 15 
van deze 50 kinderen zonder substantiele remissie desondanks tach een 'accepta-
bel' behandelingsresultaat was bereikt. Hiervoor werd een cOlnbinatie van 'harde 
data' (duur van remissie, ontbreken van verdere aanpassing van medica tic) en 
'zachte data' (retrospectief oordeel van de neuroloog) nodig geacht. 
\Vie oordeelde in de praktijk van de studie of aanvallen of bijwerkingen 
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'acceptabel' waren: de arts, de ouders of het kind? \Vaarom waren aanvallen of 
bijwerkingen soms 'acceptabel' en sams niet? Deze vragen benadrukken dat de 
traditionele, relatief simpele manier waarop de toestand van de patient met epi-
lepsie in het ZHKO kaart werd gebracht soms te beperkt is. De rapportage van 
vrijwel aIle trials en audit studies geeft slechts informatie over aanvalsfrequentie 
(b.v. het aantal dat 50% reductie bereikt in aanvalsfrequentiel of duur van remis-
sie. Infonnatie over 'acceptabele controle' van aanvallen, of 'acceptabele bijwer-
kingen' ontbreekt. Een belangrijke reden hiervoor is, cIat het ingewikkeld is om 
zulke subjectieve zaken op een belrouwbare, valide en voor onderzoekers 
bruikbare wijze te kwantiHceren. Tach is er een duidelijke trend in de klinische 
wetenschap, en zo ook in de epileplologie, om dit weI te proberen. Dit proef-
schrift geeft in de hoofdstukken 3 -7 een overzicht van de resultaten van een 
project met als doel om alternatieve uitkomstmaten te ontwikkelen, voor toe-
passing bij kinderen met (moeilijk behandelbare) epilepsie. 
9.2 Hoofdstuk 3: 
LlTERATUUROVERZICHT: Alternatieve uitkomstmaten bij epilepsie. 
In de laatste tien jaar zijn er verschillende schalen ontwikkeld am beter in 
kaart te kunnen brengen wat de effecten zijn van epilepsie op het dagelijks leven. 
In dit overzicht beperk ik mij tot schalen die zich richten op de fysieke cq klini-
sehe gevolgen van epilepsie, met name de aanvallen en de bijwerkingen van me-
dicijnen. De besproken schalen kunnen dus beschouwd worden als klinimetri-
sehe instnlmenten. Vier schalen zijn in de literatuur goed beschreven: (1) De 
sehalen van de Veterans Administration 31, die zich rkhten op aanvalsfrequentie 
en -ernst, respectievelijk bijwerkingen van AEDs. (2) De Chalfont Seizure 
Severity Scale." (3) De Liverpool Seizure Severity Scale." (4) De Epilepsy Surgery 
Inventory (ESI) en Quality of Life in Epilepsy (QOLlE) Scale. "" Deze schalen zijn 
bedoeld voor epilepsie bij volwassen patienten. Van deze schalen is de betrouw-
baarheid en validiteit onderzoeht en is sprake -zij het in beperkte tnate- van 
klinische bruikbamheid. 
Deze schalen verschillen op ten minste twee belangrijke punten: het per-
spectief (\Vie bepaalt de ernst van ziekteverschijnselen?) en de mate van specifi-
dtcit voor epilepsie. De schalen genoemd onder 1) en 2) zijn schalen die het 
perspectief van de dokter kiezen, met name de dokter beslist of iemand ergens 
last van heeft en hoe zwaar dat telt. Sehalen 3) en 4) kiezen het perspectief van 
de patient. Dit is een essentieel verschil: wat dokters vinden van de ernst van 
ziekle kan sterk afwijken van wal de patient vindt. Een belangrijk fundament van 
'kwaliteit van leven' onderzoek is, cIat men in kaart brengt wat de patient zelf 
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"indt, of probeert dit zo dicht mogelijk te benaderen. Welk perspectief men pre-
fereert zal vooral afhangen van het doel dat men met de schaal voor ogen heeft. 
Ten aanzien van het verschil in specificiteit kan het volgende worden gesteId: 
Schalen 1), 2) en 3) bevatten items die men kan opvatten als spedfiek betrek-
king hebbend op epilepsie en de gevolgen daarvan; de scha1en genoemd onder 4) 
bevatte veel items die men kan beschouwen als be trekking hebbend op de alge-
mene gezondheid (generieke items). Generieke scha1en hebben het voordeel dat 
men de gevolgen van verschillende aandoeningen kan vergelijken, maar ais na-
deel dat soms relevante specifieke gevolgen van een ziekte in zo'n schaainiet aan 
de orde komen. Epilepsie is bij uitstek een ziekte met veel unieke kemnerkcn, 
zodat een spedfieke schaal hier belangrijke voordelen biedt. 
9.3 Hoofdstukken 4·7: 
DE ONTWIKKELING VAN DRIE SCHALEN VOOR KINDEREN MET EPILEPSIE. 
Oak voor kinderen met epilepsie is er behoefte aan altematieve uitkomsuuaten 
ais aanvuiling op de traditionele. In hoofdstuk 3 kwamen wij tot de conclusie dat de 
epilepsie op de kinderleeftijd zo veel specifieke verschillen met epilepsie bij volwas-
senen kent, dat men voor onderzoek bij kinderen niet zander meer gebmik kan 
maken van de besproken schalen voor volwassen patienten. Wij besloten tot de ont-
wikkeling van schalen voor (a) aanvalsernst, (b) ernst van bijwerkingen en (c) elnst 
van beperkingen door epilepsie. Doel van de sehalen was om op gestandaardiseerde 
wijze het subjectieve oordeel over de epilepsie en de behandeling bij de 
behandelingsstrategie te kunnen betrekken. Omdat naar onze verwachting in de 
doelgroep veel kinderen niet in staat zouden zijn om zelf betrouwbare infonnatie te 
geven, hebben wij gekozen voor de ouders als bran van infonnatie. We kozen daar-
mee voor een opzet die aansloot bij algemene opvattingen over de manier waarap 
men aspecten van kwaliteit van leven van kinderen in kaart kan brengen. De schalen 
zijn zo gemaakt, dat het aan de ouders wordt overgelaten om aan te geven of bepaaI-
de verschijnselen zich voordoen en -zo ja- hoe enlstig deze zijn. 
Items voor een pilot studie werden zowel door clinici ais ouders voorgesteld. 
De definitieve schalen werden geeonstnleerd uit een verzameling van items, na ana-
lyse van materiaal uit de pilot studie. Vervolgens werden de schalen getest in een 
groep van mim 100 kinderen tussen 4 en 16 jaar, waarvan 314 Iced aan een moeilijk 
behandelbare epilepsie. BijIk1. de heUt van deze groep was lieht tot zeer ernstig gere-
tardeerd, en een deel van deze kinderen had daarbij nag andere beperkingen. De 
groep die wordt beschreven in de hoofdstukken 4-7 verschilt dus van de populatie in 
hoofdstuk 2, waar het kinderen met een recent vastgestelde epilepsie betror. 
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Hoofdstuk 4: 
DE ERNST VAN EPILEPTISCHE AANVALLEN 
Aanvalsernst is cell belangrijke aanvlliling op aanvalsfrequentie: het heeft 
wcinig betekenis om te wetcn dat cell kind 5 aanvallen per rnaand heeft zander 
daarbij over een indica tie van de ernst van de aanvallen te beschikken. Als indi-
catie voor aanvalsernst dient uu vaak de classificatie van het aanvalstype. Hieraan 
kleven eelIter belangrijke nadelen, die zijn besproken in haafdstuk 3. De door 
ons ontwikkelde schaal vaor aanvalsernst weId gebaseerd op de Liverpool 
Seizure Severity scalc15 , die werd aangepast om beantwoording door de ouders 
mogelijk te maken en weId aangevuld met nieuwe items aikomstig van neurolo-
gen en auders. 
In Appendix lA is de schaal (the Hague Seizure Severity scale, HASS) inte-
graal opgenomen. De resultaten van psychometrische analyse van de HASS waren 
kart samengevat als voIgt: Aantal items = 13. Laagste (beste) score 13; hoagste 
(slechtste) 54. Test-hertest betrouwbaarheid: Pearson r= 0.93. Interne consisten-
tie: Crohnbach's alpha= 0.85. Frequentie distributie scores: normale verdeling. 
Bij 117 kinderen met epileptische aanvallen vergeleken we de scores op de 
HASS met diverse klinische gegevens en een globaal oordeel over aanvalsernst 
door de neuroloog, middels een score op een visueel analoge schaal (VAS) van I 
(minst ernstig) tot 10 (meest ernstig). Zowel de score voor aanvalsernst van de 
ouders op de HASS als de score van de neuroloog op de VAS, toonde forse varia-
tie binnen een aanvalstype en· overlap hlssen verschiHende aanvalstypen. Scores 
waren voor beide schalen wel significant verschillend tussen graepen met (a) ab-
sences of enkelvoudig partieIe aanval1en, (b) complex particle aanvallen of (c) 
gegeneraHseerd tonisch-clonische aanvallen. De correlatiecocfficicnt tussen de 
scores van de ouders en de neurologen was 0.45 in de graep als geheel, maar waS 
niet grater dan 0.26 per groep met ten aanvalstype. Er was geen substanticle cor-
relatie lUssen de HASS scores en aanvalsfrequentie, leeftijd, duur van de epilepsie 
of geslacht. Kinderen op polytherapie en kinderen met retardatie kregen van de 
neurologen, maar niet van de ouders, een hogere score voor aanvalsernsl. 
COllclusie: Dc HASS is een betrouwbare schaal voor het kwantificeren van 
de ernst van epileptische aanvallen bij kinderen. Hoewel de schaal is gebaseerd 
01' een klinisch concept van aanvalsernst, laat de schaal de ouders veel ruimte 
am de eigen mening inzake aan- of afwezigheid van verschijnselen en hun ernst 
weer te geven. De correlatie met een globale score voor aanvalsernst door de 
neuroloog was zwak. Dit wijst er op, cIat het subjectieve oordeel van de ouders 
een aanvulling is op het oordeel van de neuroloog. Geen van beide opvattingen 
kan worden aangemerkt als 'waar" in de zin van 'ontdaan van subjectiviteit'. 
Hierbij kan men overwegen dat ouders het meest frequent getuige zijn van de 
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aanvallen en de gevolgen hiervan voor hun kind, en dat hun opvattingen wellicht 
de manier waarop het kind met de aanvallen leert omgaan sterker befnvloeden 
dan die van de neuroloog. 
Hoofdstuk 5: 
DE ERNST VAN BIJWERKINGEN 
De tweede schaal werd ontwikkeld met de bedoeling om de ernst van 'sub-
jectieve' bijwerkingen te kwantificeren. In de meeste klinische publikaties wordt 
vooral de aandacht gericht op de positieve effecten van medicatie, en vonnen de 
bijwerkingen een wat onderbelicht geheel, zowel in de 'Methods' als in de 
'Results'sectie. Dit geldt met name voor de 'klinisch acceptabele' bijwerkingen, 
terwijl ouders en kinderen in de praktijk veelvuldig melding maken van 
bijwerkingen van AEDs. Vaak blijft het hierbij onduidelijk of deze bijwerkingen 
een causaal verband hebben met de AEDs in kwestie, en is de ernst van de ge-
melde bijwerkingen moeilijk of niet objectiveerbaar. 
De schaal die wij maakten voor het kwantificeren van de ernst van bijwer-
kingen, the Hague Side Effects scale (HASES), kon niet op een bestaande schaal 
worden gebaseerd. vVij begonnen met een pilot-schaal, die uitvoerig werd aange-
past na een eerste studie bij ca. 40 kinderen. Wij kozen voor 20 frequent gerap-
porteerde, onderling samenhangende bijwerkingen. In Appendix IB is de HASES 
integraal opgenomen. De resultaten van psychometrische analyse van de HASES 
waren kort samengevat ais voIgt: Aantal items = 20. Laagste (beste) score 20; 
hoogste (slechtste) 80. Test-hertest betrouwbaarheid: Pearson r= 0.91. Interne 
consistentie: Crohnbach's alpha= 0.88. Frequentie distributie scores: scheve ver-
dding met veel lage en weinig hoge scores. 
Bij 115 kinderen die AEDs gebruikten, vergeleken we de scores op de 
HASES met die van een controlegroep van 25 kinderen die behandcld werden met 
inhalatie medicatie voor asuna (IMA). Voorts bestudeerden we de correlatie lll.et 
diverse klinische gegevens zoals het aantal AEDs en de closering, alsmede een glo-
baal oordeel over de ernst van bijwerkingen door de neuroloog op een VAS. Bij 
82% van de kinderen op AEDs en 88% van de kinderen op IMA werden een of 
meer bijwerkingen gerapporteerd. De mediane scores op de HASES waren 26 voor 
kinderen 01' AEDs en 22 voor kinderen op IMA (verschil niet Significant). Er was 
geen significant correlatic tussen het oordeel van de ouders en dat van de neuro-
loog. \Vij vonden geen Significant verschil in mediane HASES score tussen kinde-
ren op mono- of polytherapie, en geen significante conclatie met de dosering van 
AEDs. Factoren als lecftijd, geslacht, duur van epilepsie, mentale retardatie, klini-
sche remissic van aanvaUen, of recent startcn met cq verhogen van de dosis van 
een AED waren niet substantiecl van invloed op de HASES score. 
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COllclusic: De HASES meet op betrouwbare \vijze de prevalentie en ernst 
van cell aantal klachten die de cuders toeschrijven aan de door hun kinderen ge-
bruikte AEDs. De subjectieve bijwerkingen van de medica tie, zoals vastgesteld 
met de HASES, waren echter niet specifiek VDor kindercn op AEDs. We vDnden 
geen aanwijzingen voor een causale relatie tussen AEDs en de gemelde bij-
werkingcn. De validiteit van deze schaal als maat voor de ernst van bijwerkingen 
kon dus Iliet worden bevestigd. Omdat de schaal beoogd opvattingen van de cu-
ders te kwantificeren, kan de validiteit hiermede oak niet worden verworpen. 
Aangezien deze studie geen blinde en gerandomiseerde opzet kende is het moge-
lijk dat de negatieve resuhaten het gevolg waren van aanpassing van dosis en 
aantal AEDs aan de tolerantie voor AEDs van het individuele kind. Gelet op het 
bclang in de praktijk van de opvattingen van ouders inzake bijwerkingen, lijkt 
een gecontroleerde studie met de HASES zeer gewenst. 
Hoofdstuk 6: 
DE ERNST VAN BEPERKINGEN 
Een derde schaal werd ontwikkeld om de beperkingen te kwantificeren, die 
het gevolg zijn van de epilepsie. Zo adviseren clinici soms de ouders van een 
kind met epileptische aanvallen om het kind niet te laten fietsen of klimmen en 
am toezicht te houden bij activiteiten zoals zwemmen. Dergelijke beperkingen 
dienen vooral om schadclijke gevolgen van een aanval te voorkomen. Ze hebben 
ongetwijfcld ook nadelige nevencffecten, omdat ze de 'normale' activiteiten en zo 
de 'normale' ontwikkeling van een kind in de weg staan. Oak voor deze schaal 
zijn wij niet uitgegaan van een reeds bestaande schaal, en werd de inhoud van de 
schaal vooral bepaald door suggesties van ouders en analyse van gegevens uit een 
pilotstudie. De schaal richt zich dus op beperkingen die de ouders toepassen, en 
niet noodzakelijkerwijs op klinisch rationele beperkingen. 
In Appendix lC is de schaal (the Hague Restrictions in Childhood Epilepsy 
scale, HARCES) integraal opgenomen. De resultaten van psychometrische analy-
se van de HARCES waren kort samengevat als voIgt: Aantal items = 10. Laagste 
(beste) score 10; hoogste (slechtste) 40. Test-hertest betrouwbaarheid: Pearson 
r= 0.93. Interne consistentie: Crohnbach's alpha= 0.89. Frequentic distributie 
scores: scheve verde ling, veellage en weinig hoge scores. 
Bij 122 kinderen met epileptische aanvallen in het voorafgaande jaar, verge-
leken we de score 01' de HARCES met een aantal klinische variabelen. Na een 
jaar herhaaiden we de meting met de HARCES bij 78 opeenvolgende kinderen. 
De neuroloog had beperkingen geadviseercl bij 2/3 van de 122 kinderen. 
Kinderen aan wie een dergclijk advies was gegeven hadden een hogere score op 
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de HARCES (18 vs 13, p<O.OOI). Andere klinische en demografische factoren 
waren niet substantieel geassocieerd mct de HARCES score, inclusief factoren als 
'rcmissie van 3 tot 12 maanden', voorspelbaarheid van aanvallen, bijkomendc 
beperkingen door retardatie of verlammingen, leefliid of aanvalsemst (HASS). Na 
een jaar waren de mediane scores significant verschillend tussen kinderen Inet 
(a) cen remissie >1 jaar, (b) remissie tussen 3 en 12 maandcn en (c) geen remis-
sie (11,5 vs 14 vs 20, p=0.003). In de groep als geheel waren de scores na een 
iaar sterk gecorreleerd met de eerste scores (r=0.75). 
Conclllsie: Wij vonden een significante invloed van het neurologisch advies 
inzake beperkingen op de activiteiten die in de HARCES aan de orde komen. Een 
remissie van meer dan een jaar was de enige klinische factor die met een lagere 
HARCES score was geassocieerd. Het is aannemelijk dat andere -niet onclerzoch-
te- factoren, zoals de mate van bezorgdheid van ouders, een belangrijke invloed 
had den op het aantal en de ernst van beperkingen die aan kinderen lllet epilepsie 
werden opgelegd. Dc HARCES kan nuttig zijn om deze beperkingen te inventari-
seren en te bespreken, en voor het verbeteren van de balans tussen beperkingen 
en het risico op verwondingen of andere complicatics van epileptische aanvallen. 
9.4 DISCUSSIE 
Om de redenen voor kettzes bij de behandeling van epilepsie goed te begrij-
pen en de uitkomst van de behancleling optimaal in kaart te brengen, schieten de 
traditioncle parameters tekort. vVij bespraken drie door ens ont\vikkelde schalen 
die kunnen dienen als aanvulling op de traditionele klinische parameters bij Oll-
derzoek naar de uitkomst van behandeling van kinderepilepsie. De schalen vol-
deden aan basale psychometrische eisen va or betrouwbaarheid. Dc validiteit van 
deze schalen kwam aan de orde in aanvullende studies, waarbij een vergelijking 
werd gemaakt met de 'globale klinische indruk' van de neuroloog en met diverse 
klinische variabelen. Aile drie schalen voegen naar onze mening nieuwe informa-
tie toe aan de bekende klinische parameters. De validiteit van deze infonnatie 
kon met name voor de schalen voor aanvalsernst en beperkingen worden on-
derbotlwd. De schaal voor bijwerkingen voldoet in die zin weI aan de verwach-
ting dat hij naar aUe waarschijnlijkheid meet wat ouders vinden van bijwerkin-
gen van AEDs, maar we konden niet waarschijnlijk maken dat de gerapporteerde 
bijwerkingen ook daadwerkelijk in een causale relatie met het gebruik van AEDs 
stonden. 
De schalen werden onderzocht in een populatie waarin kinderen met een 
therapieresistente epilepsie domineerden. Va or een grocp kinderen met een rc-
cent begonnen epilepsie zal in ieder geval de HASS vermoedelijk van minder 
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waarde zijn: De meeste van deze kinderen komen snel in een complete remissic. 
Wei zou de schaal kunnen dienen om de uitgangspositie van twee of meer groe-
pen met elkaar te vergelijken. 
Van geen van de schalen staat vast dat ze voldoende gevoelig zijn voor 
verandering, hetgeen een belangrijke eis is voor bruikbaarheid bij wetenschappe-
lijk onderzoek. In de groep met persisterende epileptische aanvallen, werd na cen 
jaar de HASS herhaald, en werd geen significant verschil gevonden in aanvals-
ernst. 115 Het is echter aannemelijk dat deze bevindingen wijzen op de 'onbe-
handelbaarhcid' van de aanvallen bij deze groep kinderen, en niet op ongevoelig-
heid voor het meten van verandering van de HASS. Derhalve is het van belang de 
opbrengst van de HASS en de HASES verder te onderzoeken in vergelijkende stu-
dies van AEDs met een blinde en gerandomiseerde opzet. Het is met name van 
belang am na te gaan of de schalen kunnen bijdragen aan het vinden van een kli-
nisch relevant verschil in effectiviteit of bijwerkingen tussen verschilIende AEDs. 
Binnen enkele jaren verwachten wij hierover naderc gegevens te kunnell publice-
reno 
01' grond van leeftijd en communicatieve vaardigheden kwam zeker de 
helft van de kinderen in on5 onderzoek niet voor zelf-rapportage in aanmerking. 
Het is uiteraard belangrijk om na te gaan, hoe kinderen die daartoe weI in staat 
zijn, er zelf over denken. Met een Amerikaanse vertaling van onze schalen, wordt 
inmiddcls getracht om de mening van ouders en kinderen te vergelijken, in een 
populatie van patienten uit New York.S3 De voorlopige conc1usie van deze studie 
is, dat ouders en kinderen in hoge mate dezelfde mening zijn toegedaan, aileen 
schatten kinderen zelf de ernst van hun beperkingen lager in dan hun ouders. 
De beperkingen van de traditionele manier om de resultaten van behande-
ling van epilepsie in kaart te brengen worden steeds meer erkend. De interesse in 
alternatieve methoden, zoals bechreven in dit proefschrift, neemt toe. \Nij hop en 
dat onze schalen ook door anderen gebruikt zuBen worden, en stellen ze am 
deze reden dan oak beschikbaar aan gelnteresseerde clinici en ondcrzoekers. 
Dit hoofdstuk is deels gebaseerd op een artikel, dat is verschellcn in Epilepsie 
Bulletin 1997;25:46-49. 
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APPENDIX 1A: HAAGSE SCHAAL VOOR DE ERNST VAN EPILEPTISCHE AANVALLEN 
(The Hague Seizure Severity scale) 
Deze vragen gaan over de aanvallen die Uw kind had in de afgelopen drie 
maanden. Wilt U per vraag a.u.h. maar cen antwoord omcirkelen? 
1. Hoe vaak was er bewustzijnsdaling bij de aanvallcn? 
a. altijd 
b. mecstal 
c. soms 
d. nooit 
2. Hoe lang vond u de bewustzijnsdaling dan meestal duren 
(gerekend vanaf hel begin lOldal uw kind weer bijkomtl? 
a. zeer lang 
b. lang 
c. kort 
d. zeer kort 
e. niel van toepassing. er was nooit bewustzijnsdaling 
bij de aanvallen 
3. Hoe ernstig waren de aanvallen in het algemeen? 
a. zeer ernstig 
b. matig ernstig 
c. mild 
d. zeer mild 
4. Traden er bij de aanvallen schokken of stij£krampen op in 
de armen of benen? 
a. allijd 
b. meestal 
c. soms 
d. nooit 
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5. Hoe lang duurden meestal de schokken of stijfkrampen bij een aanval? 
a. zeerlang 
b. lang 
c. kart 
d. zeer kort 
e. niet van toe passing, geen schokken of stijfkrampen 
6. Hoe opvallend waren de verschijnselen van een aanval? 
a. zeer opval1end, iedereen zal een aanval opmerken 
b. matig opvallend, de meeste mensen zuBen een aanval 
weI opmerken 
c. weinig opvallend, de tn.eeste mensen zullen een aanval 
niet opmerken 
d. niet opvallend, je moet goed opletten am een aanval te 
zien 
7. Hoe vaak was uw kind verward tijdens of direct na een 
aanval? 
a. altijd 
b. tn.eestal 
c. soms 
d. nooit 
8. Hoe vaak plaste uw kind in zijnJhaar broek bij een aanval? 
a. altijd 
b. meestal 
C. soms 
d. nooit 
e. onbekend, mijn kind heeft (nag) geen controle over het plassen 
9. Hoe vaak beet uw kind tijdens cen aanval op zijnlhaar 
tong of wang? 
a. altijd 
b. meestal 
c. soms 
d. nooit 
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10. Hoe "aak raakte uw kind gewond bij een aanval, met 
uitzondering van de tongbeet? 
a. altijd 
b. meestal 
C. soms 
d.nooit 
11. Was uw kind slaperig nadat de aanval over was? 
(Het maakt niet uit of dit het gevolg was van de aanval 
of van het eventueel gebruiken noodmedicatie als Stesolid.) 
a. altijd 
h. meestal 
c. soms 
d. nooit 
12. Had uw kind na de aanvallast van misselijkheid, hoofdpijn en/of spierpijn? 
a. altijd 
b. meestal 
c. $oms 
d. nooit 
c. onbekend. mijn kind zou dit niet duidelijk kunnen 
maken 
13. Hoc lang duurde het na de aanval totdat uw kind weer 
nonnaal actief kon zijn? 
a. zeer lang 
b.lang 
c. kort 
d. zeer kart of direct na de aanval 
AIle items hebben 4 of 5 subjectieve respons-categorieen (b.v. altijd, meestal. 
SOll1S of nooH). Score per item: 1 punt voor meest gunstige antwoord, tot 5 
(vraag 2 en 5) of 4 (ane overige vragen) punten voor meest ongunstige 
antwoord. 
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APPENDIX 1B: HAAGSE SCHAAL VOOR BIJWERKINGEN 
(the Hague Side Effects Scale) 
lEEST V A.V.E. EERST DEZE TOEllCHTlNG! 
De volgende vragen gaan over bijwerkingen van de medicijnen tegen epilcpsie. 
Ais lIW kind last heeft van onzekerheid bij het lopen, en 1I denkt dat dat komt 
door de medicijnen, noemen we het een bijwerking. Als uw kind moeilijk loopt 
om een andere reden (bij voorbeeld een handicap of een gebroken been) telt dat 
niet als bijwerking. 
Betekenis van de antwoorden: 
a = ernstig 
b = matig ernstig 
c = mild 
d = nce/niet van toepassinglniet te beoordelen Lv.m. handicap 
Bcmerkte U bij Uw kind in de afgelopen drie maanden de volgende bijwerkingen 
van de medicijnen tegen epilepsie? Wilt U per vraag a.u.b. maar cen antwoord 
omcirkelen? 
1 sufheid, slaperigheid a. b. c. d. 
2 duizeligheid a. b. c. d. 
3 onzekerheid bij lopen a. b. c. d. 
4 vallen a. b. c. d. 
5 misselijkheid a. b. c. d. 
6 moeizame ontlasting a. b. c. d. 
7 diarree a. b. c. d. 
8 beven, trillen a. b. c. d. 
9 mocite met spreken <l. b. c. d. 
10 dubbelzien, wazig zien a. b. c. d. 
11 hoofdpijn a. b. c. d. 
12 vennoeidheid a. b. c. d. 
13 vermindering van eetlust a. b. c. d. 
14 depressiviteit <l. b. c. d. 
15 druk gedrag, overbewegelijkheid a. h. c. d. 
16 driftbuien, agressie a. b. c. d. 
17 traagheid, loomheid a. b. c. d. 
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18 verminderde schoolprestaties 
19 concentratiestoornis 
20 verstoord gedrag 
Als u bij uw kind nog bijwerkingen hebt bemerkt, 
die niel zijn genoemd, kunt u die hieronder invullen: 
2l 
a. b. c. d. 
a. b. c. d. 
a. b. c. d. 
a. b. c. d. 
AIle items hebben de volgende subjectieve respons-categorieen: ernstig, matig 
ernslig, mild, nee/niet van toepassinglniet te beoorrlelen Lv.m. handicap. Score 
per item: 1 punt voor meest gunstige antwoord, tot 4 punten yoor meest ongun-
stige antwoord. 
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APPENDIX 1C: HAAGSE SCHAAL VOOR BEPERKINGEN BIJ KINDEREN MET EPILEPSIE 
(the Hague Restrictions in Childhood Epilepsy Scale) 
De volgende vragen gaan over de beperkingen die uw kind heeft door zijn/haar 
epileptische aanvallen. Wanneer uw kind weI kan fietsen, maar dat niet mag, 
vanwege de kans op een aanval, noemen we dat een beperking door de epilepsie. 
\Vanneer LlW kind niet kan Hetsen om een andere reden (bij voorbeeld omdat 
hijlzij te klein is, of een handicap heeft) telt dat hier niet mee. Wilt U per vraag 
a.Ll.b. maar een antwoord omcirkelen? 
1. Is er extra toezicht nodig bij de dagelijkse activiteiten van uw kind iV111. de 
kans op een aanval (de epilepsie)? 
a. zeer veel 
b. veel 
c. weinig 
d. geen 
2. \Vorden er speciale maatregelen getroffen bij de dagelijkse activiteiten van 
uw kind vanwege de epilepsie (bij voorbeeld dragen van helm, speciale 
badmuts)? 
a. altijd 
b. meestal 
c. soms 
d. nooit 
3. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om 
binnen (in lmls) te speIen? 
a. zeer veel 
b. veel 
c. weinig 
d. geen 
4. Heeft de epilepsie invioed op de mate van vrijheid die uw kind heeft om 
buiten (op straat) te spelen? 
a. zeer veel 
b. veel 
c. weinig 
d. geen 
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5. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om te 
zwemmen? 
a. zeer veel 
b. vee! 
c. weinig 
d. geen 
6. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om te 
sporten (met uitzondering van zwemmen)? 
a. zeer veel 
b. vee! 
c. weinig 
d. geen 
7. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om 
aan het verkeer deel te nemen (bij voorbeeld te gaan Hetsen)? 
a. zeer veel 
b. veel 
c. weinig 
d. geen 
8. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om te 
gaan logeren? 
a. zeer veel 
b. veel 
c. weinig 
d. geen 
9. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om 
naar feestjes of partijtjes te gaan? 
a. zeer veel 
b. veel 
c. weinig 
d. gem 
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10. Heeft de epilepsie invloed op de mate van vrijheid die uw kind heeft om 
aan de gymles dee! te nemen (bij voorbeeld in het wandrek te klimmen)l 
a. zeer veel 
b. vee! 
c. weinig 
d.geen 
Score per item: 1 punt voor meest gunstige antwoord, tot 4 punten voor meest 
onguIlSlige antwoord. 
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